https://trial.medpath.com/news/fda-approves-subcutaneous-atezolizumab-and-hyaluronidase-tqjs-for-use-in-all-onclive 2024-09-12T22:34:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-subcutaneous-atezolizumab-and-hyaluronidase-tqjs-for-use-in-all-onclive 2024-09-12T22:34:38+00:00 weekly 0.7 https://trial.medpath.com/news/gilead-s-twice-yearly-lenacapavir-for-hiv-prevention-reduced-hiv-infections-by-96-and 2024-09-12T22:16:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gilead-s-twice-yearly-lenacapavir-for-hiv-prevention-reduced-hiv-infections-by-96-and 2024-09-12T22:16:58+00:00 weekly 0.7 https://trial.medpath.com/news/cvrx-touts-positive-two-year-data-for-heart-failure-neuromodulation-device 2024-09-12T22:15:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cvrx-touts-positive-two-year-data-for-heart-failure-neuromodulation-device 2024-09-12T22:15:16+00:00 weekly 0.7 https://trial.medpath.com/news/neurocrine-biosciences-provides-update-on-eruditetm-phase-2-data-for-luvadaxistat-in 2024-09-12T21:08:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neurocrine-biosciences-provides-update-on-eruditetm-phase-2-data-for-luvadaxistat-in 2024-09-12T21:08:32+00:00 weekly 0.7 https://trial.medpath.com/news/alio-launches-calibration-and-validation-cava-study-to-expand-alio-platform-s-fda-biospace 2024-09-12T21:08:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alio-launches-calibration-and-validation-cava-study-to-expand-alio-platform-s-fda-biospace 2024-09-12T21:08:30+00:00 weekly 0.7 https://trial.medpath.com/news/immuneering-announces-positive-initial-phase-2a-data 2024-09-12T21:06:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immuneering-announces-positive-initial-phase-2a-data 2024-09-12T21:06:34+00:00 weekly 0.7 https://trial.medpath.com/news/bridgebio-grows-up-trims-pipeline-as-it-leans-into-late-stage-assets-biospace 2024-09-12T20:44:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bridgebio-grows-up-trims-pipeline-as-it-leans-into-late-stage-assets-biospace 2024-09-12T20:44:26+00:00 weekly 0.7 https://trial.medpath.com/news/heartsciences-provides-business-update-and-reports-first-quarter-fiscal-2025-financial-results 2024-09-12T20:20:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/heartsciences-provides-business-update-and-reports-first-quarter-fiscal-2025-financial-results 2024-09-12T20:20:31+00:00 weekly 0.7 https://trial.medpath.com/news/zambon-announces-publication-of-phase-3-promis-i-and-ii-study-results-in-the-lancet 2024-09-12T20:13:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zambon-announces-publication-of-phase-3-promis-i-and-ii-study-results-in-the-lancet 2024-09-12T20:13:06+00:00 weekly 0.7 https://trial.medpath.com/news/association-of-statin-metformin-and-aspirin-use-with-hepatocellular-carcinoma-in-the-all-of 2024-09-12T18:08:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/association-of-statin-metformin-and-aspirin-use-with-hepatocellular-carcinoma-in-the-all-of 2024-09-12T18:08:42+00:00 weekly 0.7 https://trial.medpath.com/news/cancer-stage-vs-mortality-end-points-in-randomized-clinical-trials-of-cancer-screening 2024-09-12T17:58:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cancer-stage-vs-mortality-end-points-in-randomized-clinical-trials-of-cancer-screening 2024-09-12T17:58:30+00:00 weekly 0.7 https://trial.medpath.com/news/spark-biomedical-awarded-national-institute-on-drug-abuse-funding-to-develop-ai-morningstar 2024-09-12T17:55:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/spark-biomedical-awarded-national-institute-on-drug-abuse-funding-to-develop-ai-morningstar 2024-09-12T17:55:08+00:00 weekly 0.7 https://trial.medpath.com/news/digital-twin-technology-may-serve-as-soc-control-in-gvhd-trial-targeted-oncology 2024-09-12T17:46:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/digital-twin-technology-may-serve-as-soc-control-in-gvhd-trial-targeted-oncology 2024-09-12T17:46:55+00:00 weekly 0.7 https://trial.medpath.com/news/omrx-oncology-launches-to-advance-investigational-oral-checkpoint-inhibitor-designed-to 2024-09-12T17:46:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/omrx-oncology-launches-to-advance-investigational-oral-checkpoint-inhibitor-designed-to 2024-09-12T17:46:25+00:00 weekly 0.7 https://trial.medpath.com/news/sansum-diabetes-research-institute-is-actively-recruiting-patients-for-pediatric-clinical-trials 2024-09-12T17:25:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sansum-diabetes-research-institute-is-actively-recruiting-patients-for-pediatric-clinical-trials 2024-09-12T17:25:13+00:00 weekly 0.7 https://trial.medpath.com/news/oxford-heartbeat-completes-patient-recruitment-in-trial-evaluating-presize-neurovascular-software 2024-09-12T17:19:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oxford-heartbeat-completes-patient-recruitment-in-trial-evaluating-presize-neurovascular-software 2024-09-12T17:19:54+00:00 weekly 0.7 https://trial.medpath.com/news/use-of-21-valent-pneumococcal-conjugate-vaccine-among-u-s-adults-cdc 2024-09-12T17:03:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/use-of-21-valent-pneumococcal-conjugate-vaccine-among-u-s-adults-cdc 2024-09-12T17:03:44+00:00 weekly 0.7 https://trial.medpath.com/news/tumor-induced-b-cell-changes-reveal-potential-biomarker-for-treatment-response-in-triple 2024-09-12T16:25:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tumor-induced-b-cell-changes-reveal-potential-biomarker-for-treatment-response-in-triple 2024-09-12T16:25:31+00:00 weekly 0.7 https://trial.medpath.com/news/fda-gives-authorization-for-first-over-the-counter-hearing-aid-software-device-hcplive 2024-09-12T16:23:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-gives-authorization-for-first-over-the-counter-hearing-aid-software-device-hcplive 2024-09-12T16:23:23+00:00 weekly 0.7 https://trial.medpath.com/news/yunu-extends-free-cancer-center-use-of-platform-for-all-children-s-oncology-group-clinical-trials 2024-09-12T15:57:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/yunu-extends-free-cancer-center-use-of-platform-for-all-children-s-oncology-group-clinical-trials 2024-09-12T15:57:01+00:00 weekly 0.7 https://trial.medpath.com/news/curevac-partner-gsk-announces-positive-phase-2-data-from-seasonal-influenza-mrna 2024-09-12T15:45:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/curevac-partner-gsk-announces-positive-phase-2-data-from-seasonal-influenza-mrna 2024-09-12T15:45:46+00:00 weekly 0.7 https://trial.medpath.com/news/medtronic-scores-fda-approvals-for-several-new-therapies-to-drive-sales-star-tribune 2024-09-12T15:37:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medtronic-scores-fda-approvals-for-several-new-therapies-to-drive-sales-star-tribune 2024-09-12T15:37:04+00:00 weekly 0.7 https://trial.medpath.com/news/shorter-course-radiation-better-option-for-breast-cancer-patients-than-conventional-schedule 2024-09-12T15:25:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/shorter-course-radiation-better-option-for-breast-cancer-patients-than-conventional-schedule 2024-09-12T15:25:40+00:00 weekly 0.7 https://trial.medpath.com/news/vera-therapeutics-completes-enrollment-for-primary-endpoint-in-pivotal-phase-3-origin-3 2024-09-12T15:16:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vera-therapeutics-completes-enrollment-for-primary-endpoint-in-pivotal-phase-3-origin-3 2024-09-12T15:16:46+00:00 weekly 0.7 https://trial.medpath.com/news/richmond-clinical-trials-seeks-volunteers-for-vaccine-studies 2024-09-12T15:05:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/richmond-clinical-trials-seeks-volunteers-for-vaccine-studies 2024-09-12T15:05:24+00:00 weekly 0.7 https://trial.medpath.com/news/three-biotech-firms-secure-700m-in-major-ipo-wave-signaling-market-momentum 2024-09-12T15:02:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/three-biotech-firms-secure-700m-in-major-ipo-wave-signaling-market-momentum 2024-09-12T15:02:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-arthroscopic-knee-cartilage-repair-orthopedics-this-week 2024-09-12T14:45:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-arthroscopic-knee-cartilage-repair-orthopedics-this-week 2024-09-12T14:45:32+00:00 weekly 0.7 https://trial.medpath.com/news/trimodal-therapy-promising-for-recurrent-high-grade-t1-bladder-cancer 2024-09-12T14:20:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/trimodal-therapy-promising-for-recurrent-high-grade-t1-bladder-cancer 2024-09-12T14:20:35+00:00 weekly 0.7 https://trial.medpath.com/news/an-injectable-hiv-prevention-drug-is-highly-effective-but-wildly-expensive 2024-09-12T14:16:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/an-injectable-hiv-prevention-drug-is-highly-effective-but-wildly-expensive 2024-09-12T14:16:21+00:00 weekly 0.7 https://trial.medpath.com/news/matinee-mepolizumab-significantly-reduces-copd-exacerbations-pulmonology-advisor 2024-09-12T13:55:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/matinee-mepolizumab-significantly-reduces-copd-exacerbations-pulmonology-advisor 2024-09-12T13:55:17+00:00 weekly 0.7 https://trial.medpath.com/news/easd-2024-hightide-therapeutics-presents-oral-reports-of-phase-2-studies-highlighting 2024-09-12T13:20:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/easd-2024-hightide-therapeutics-presents-oral-reports-of-phase-2-studies-highlighting 2024-09-12T13:20:21+00:00 weekly 0.7 https://trial.medpath.com/news/tcbp-announces-first-patient-completed-the-full-fose-regimen-in-achieve-clinical-trial 2024-09-12T13:00:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tcbp-announces-first-patient-completed-the-full-fose-regimen-in-achieve-clinical-trial 2024-09-12T13:00:32+00:00 weekly 0.7 https://trial.medpath.com/news/high-adderall-dose-linked-to-alarming-risk-of-mental-health-episodes 2024-09-12T12:49:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/high-adderall-dose-linked-to-alarming-risk-of-mental-health-episodes 2024-09-12T12:49:30+00:00 weekly 0.7 https://trial.medpath.com/news/f2g-raises-100m-to-bring-antifungal-drug-back-to-fda-biopharma-dive 2024-09-12T12:44:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/f2g-raises-100m-to-bring-antifungal-drug-back-to-fda-biopharma-dive 2024-09-12T12:44:03+00:00 weekly 0.7 https://trial.medpath.com/news/icecure-announces-fda-advisory-panel-meeting-date-for-marketing-authorization-pr-newswire 2024-09-12T12:33:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/icecure-announces-fda-advisory-panel-meeting-date-for-marketing-authorization-pr-newswire 2024-09-12T12:33:17+00:00 weekly 0.7 https://trial.medpath.com/news/alzheimer-s-clinical-trials-face-critical-diversity-challenge-experts-call-for-inclusive-enrollment 2024-09-12T12:23:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alzheimer-s-clinical-trials-face-critical-diversity-challenge-experts-call-for-inclusive-enrollment 2024-09-12T12:23:40+00:00 weekly 0.7 https://trial.medpath.com/news/sernova-announces-new-positive-data-from-phase-i-ii-trial-regarding-islet-survival-and-function 2024-09-12T12:17:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sernova-announces-new-positive-data-from-phase-i-ii-trial-regarding-islet-survival-and-function 2024-09-12T12:17:04+00:00 weekly 0.7 https://trial.medpath.com/news/sinopia-secures-phase-ii-sbir-grant-from-the-national-institute-of-dental-and-craniofacial 2024-09-12T12:17:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sinopia-secures-phase-ii-sbir-grant-from-the-national-institute-of-dental-and-craniofacial 2024-09-12T12:17:02+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-announces-positive-headline-data-from-phase-ii-seasonal-influenza-mrna-vaccine-programme 2024-09-12T12:04:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gsk-announces-positive-headline-data-from-phase-ii-seasonal-influenza-mrna-vaccine-programme 2024-09-12T12:04:25+00:00 weekly 0.7 https://trial.medpath.com/news/bright-minds-biosciences-initiates-the-breakthrough-study-a-phase-2-trial-of-bmb-101 2024-09-12T12:00:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bright-minds-biosciences-initiates-the-breakthrough-study-a-phase-2-trial-of-bmb-101 2024-09-12T12:00:44+00:00 weekly 0.7 https://trial.medpath.com/news/vironexis-biotherapeutics-launches-with-fda-clearance-of-ind-application-for-first-ever 2024-09-12T11:49:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vironexis-biotherapeutics-launches-with-fda-clearance-of-ind-application-for-first-ever 2024-09-12T11:49:40+00:00 weekly 0.7 https://trial.medpath.com/news/summit-therapeutics-raises-235m-for-cancer-drug-trials-tipranks-com 2024-09-12T11:36:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/summit-therapeutics-raises-235m-for-cancer-drug-trials-tipranks-com 2024-09-12T11:36:12+00:00 weekly 0.7 https://trial.medpath.com/news/world-first-florey-research-aims-to-rapidly-and-accurately-screen-drugs-to-treat-mnd 2024-09-12T11:31:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/world-first-florey-research-aims-to-rapidly-and-accurately-screen-drugs-to-treat-mnd 2024-09-12T11:31:12+00:00 weekly 0.7 https://trial.medpath.com/news/fulcrum-therapeutics-announces-topline-results-from-phase-3-reach-clinical-trial-of 2024-09-12T11:23:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fulcrum-therapeutics-announces-topline-results-from-phase-3-reach-clinical-trial-of 2024-09-12T11:23:42+00:00 weekly 0.7 https://trial.medpath.com/news/comparable-disease-activity-drug-persistence-in-patients-with-jia-who-switch-to-biosimilars 2024-09-12T11:02:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/comparable-disease-activity-drug-persistence-in-patients-with-jia-who-switch-to-biosimilars 2024-09-12T11:02:23+00:00 weekly 0.7 https://trial.medpath.com/news/positive-phase-ii-bolsters-aura-bioscience-s-confidence-in-vdc-based-therapy-for-ocular 2024-09-12T10:47:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/positive-phase-ii-bolsters-aura-bioscience-s-confidence-in-vdc-based-therapy-for-ocular 2024-09-12T10:47:34+00:00 weekly 0.7 https://trial.medpath.com/news/moderna-slashes-research-spending-trims-pipeline-as-it-looks-to-regain-footing-morningstar 2024-09-12T10:12:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/moderna-slashes-research-spending-trims-pipeline-as-it-looks-to-regain-footing-morningstar 2024-09-12T10:12:44+00:00 weekly 0.7 https://trial.medpath.com/news/weight-loss-drug-zepbound-may-work-better-in-women-than-men-healthday 2024-09-12T10:01:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/weight-loss-drug-zepbound-may-work-better-in-women-than-men-healthday 2024-09-12T10:01:52+00:00 weekly 0.7 https://trial.medpath.com/news/key-paediatric-milestone-reached-in-dimerix-s-kidney-disease-drug-trial-stockhead 2024-09-12T09:48:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/key-paediatric-milestone-reached-in-dimerix-s-kidney-disease-drug-trial-stockhead 2024-09-12T09:48:48+00:00 weekly 0.7 https://trial.medpath.com/news/doherty-clinical-trials-to-conduct-trial-of-australian-developed-needle-free-vaccine-for-avian 2024-09-12T09:48:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/doherty-clinical-trials-to-conduct-trial-of-australian-developed-needle-free-vaccine-for-avian 2024-09-12T09:48:13+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-to-neuraptive-s-ntx-001 2024-09-12T09:36:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-breakthrough-therapy-designation-to-neuraptive-s-ntx-001 2024-09-12T09:36:13+00:00 weekly 0.7 https://trial.medpath.com/news/alzheimer-s-drugs-may-work-in-whole-new-way-study-finds 2024-09-12T09:09:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alzheimer-s-drugs-may-work-in-whole-new-way-study-finds 2024-09-12T09:09:03+00:00 weekly 0.7 https://trial.medpath.com/news/crispr-fixes-multiple-dystrophin-duplications-in-dmd-patient-cells 2024-09-12T09:03:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/crispr-fixes-multiple-dystrophin-duplications-in-dmd-patient-cells 2024-09-12T09:03:22+00:00 weekly 0.7 https://trial.medpath.com/news/pbm-transparency-crisis-industry-expert-calls-for-reform-to-improve-drug-access-and-pricing 2024-09-12T08:21:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pbm-transparency-crisis-industry-expert-calls-for-reform-to-improve-drug-access-and-pricing 2024-09-12T08:21:00+00:00 weekly 0.7 https://trial.medpath.com/news/cd137-antibodies-clinical-trials-market-opportunity-yahoo-finance 2024-09-12T08:16:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cd137-antibodies-clinical-trials-market-opportunity-yahoo-finance 2024-09-12T08:16:11+00:00 weekly 0.7 https://trial.medpath.com/news/september-12-2024-nih-collaboratory-biostatisticians-evaluate-analytic-models-for 2024-09-12T08:05:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/september-12-2024-nih-collaboratory-biostatisticians-evaluate-analytic-models-for 2024-09-12T08:05:48+00:00 weekly 0.7 https://trial.medpath.com/news/ryvu-therapeutics-reports-2024-half-year-financial-results-and-provides-corporate-update 2024-09-12T08:03:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ryvu-therapeutics-reports-2024-half-year-financial-results-and-provides-corporate-update 2024-09-12T08:03:40+00:00 weekly 0.7 https://trial.medpath.com/news/novotech-publishes-report-on-research-into-endometrial-cancer-a-leading-cause-of-massbio 2024-09-12T06:38:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novotech-publishes-report-on-research-into-endometrial-cancer-a-leading-cause-of-massbio 2024-09-12T06:38:00+00:00 weekly 0.7 https://trial.medpath.com/news/novotech-report-analyses-epilepsy-research-trends-finding-more-than-4000-clinical-massbio 2024-09-12T06:37:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novotech-report-analyses-epilepsy-research-trends-finding-more-than-4000-clinical-massbio 2024-09-12T06:37:59+00:00 weekly 0.7 https://trial.medpath.com/news/novotech-liver-cancer-research-landscape-report-finds-1700-trials-initiated-globally 2024-09-12T06:37:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novotech-liver-cancer-research-landscape-report-finds-1700-trials-initiated-globally 2024-09-12T06:37:58+00:00 weekly 0.7 https://trial.medpath.com/news/new-report-highlights-global-trends-and-advances-in-chronic-lymphocytic-leukemia-massbio 2024-09-12T06:37:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-report-highlights-global-trends-and-advances-in-chronic-lymphocytic-leukemia-massbio 2024-09-12T06:37:56+00:00 weekly 0.7 https://trial.medpath.com/news/bmi-s-relation-to-cancer-therapy-mortality-risks-not-so-straightforward-eurekalert 2024-09-12T05:32:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bmi-s-relation-to-cancer-therapy-mortality-risks-not-so-straightforward-eurekalert 2024-09-12T05:32:32+00:00 weekly 0.7 https://trial.medpath.com/news/innate-pharma-reports-first-half-2024-business-update-and-financial-results-morningstar 2024-09-12T05:14:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/innate-pharma-reports-first-half-2024-business-update-and-financial-results-morningstar 2024-09-12T05:14:16+00:00 weekly 0.7 https://trial.medpath.com/news/press-release-sanofi-radiomedix-and-orano-med-announce-licensing-agreement-on-next 2024-09-12T05:12:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/press-release-sanofi-radiomedix-and-orano-med-announce-licensing-agreement-on-next 2024-09-12T05:12:28+00:00 weekly 0.7 https://trial.medpath.com/news/new-treatment-option-for-graves-disease-finally-on-the-horizon 2024-09-12T05:00:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-treatment-option-for-graves-disease-finally-on-the-horizon 2024-09-12T05:00:07+00:00 weekly 0.7 https://trial.medpath.com/news/in-depth-report-on-global-oesophageal-cancer-clinical-trials-now-available-massbio 2024-09-12T04:47:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/in-depth-report-on-global-oesophageal-cancer-clinical-trials-now-available-massbio 2024-09-12T04:47:43+00:00 weekly 0.7 https://trial.medpath.com/news/alx-oncology-s-evorpacept-gains-momentum-with-fda-fast-track-designations 2024-09-12T02:38:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alx-oncology-s-evorpacept-gains-momentum-with-fda-fast-track-designations 2024-09-12T02:38:26+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-development-of-gamma-delta-t-cell-therapy-inb-400-paused-in-glioblastoma 2024-09-12T02:10:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-development-of-gamma-delta-t-cell-therapy-inb-400-paused-in-glioblastoma 2024-09-12T02:10:12+00:00 weekly 0.7 https://trial.medpath.com/news/multimodal-analgesia-approach-in-acute-low-back-pain-management-a-phase-iii-study-of 2024-09-12T02:06:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/multimodal-analgesia-approach-in-acute-low-back-pain-management-a-phase-iii-study-of 2024-09-12T02:06:48+00:00 weekly 0.7 https://trial.medpath.com/news/two-stage-screening-for-obstructive-sleep-apnea-in-the-primary-practice-setting 2024-09-12T02:05:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/two-stage-screening-for-obstructive-sleep-apnea-in-the-primary-practice-setting 2024-09-12T02:05:09+00:00 weekly 0.7 https://trial.medpath.com/news/matregenix-awarded-three-phase-ii-sbir-and-sttr-contracts-from-the-department-of-the-air-force 2024-09-12T00:55:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/matregenix-awarded-three-phase-ii-sbir-and-sttr-contracts-from-the-department-of-the-air-force 2024-09-12T00:55:18+00:00 weekly 0.7 https://trial.medpath.com/news/kintara-therapeutics-provides-update-on-corporate-developments-and-rem-001-clinical-study 2024-09-12T00:31:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kintara-therapeutics-provides-update-on-corporate-developments-and-rem-001-clinical-study 2024-09-12T00:31:16+00:00 weekly 0.7 https://trial.medpath.com/news/global-research-community-applies-covid-19-lessons-to-combat-african-mpox-emergency 2024-09-12T00:29:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/global-research-community-applies-covid-19-lessons-to-combat-african-mpox-emergency 2024-09-12T00:29:21+00:00 weekly 0.7 https://trial.medpath.com/news/is-the-hype-about-a-new-non-opioid-analgesic-justified-pain-news-network 2024-09-12T00:15:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/is-the-hype-about-a-new-non-opioid-analgesic-justified-pain-news-network 2024-09-12T00:15:38+00:00 weekly 0.7 https://trial.medpath.com/news/hydroxychloroquine-provides-moderate-covid-19-prevention-large 2024-09-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hydroxychloroquine-provides-moderate-covid-19-prevention-large 2024-09-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-effectiveness-safety-and-compliance-of-two 2024-09-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-effectiveness-safety-and-compliance-of-two 2024-09-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/easd-2024-survodutide-shows-promise-in-overweight-obesity-and-mash 2024-09-11T23:54:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/easd-2024-survodutide-shows-promise-in-overweight-obesity-and-mash 2024-09-11T23:54:12+00:00 weekly 0.7 https://trial.medpath.com/news/a-phase-ii-study-of-neoadjuvant-nivolumab-and-nab-paclitaxel-followed-by-urotoday 2024-09-11T23:46:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-phase-ii-study-of-neoadjuvant-nivolumab-and-nab-paclitaxel-followed-by-urotoday 2024-09-11T23:46:09+00:00 weekly 0.7 https://trial.medpath.com/news/the-foundation-for-the-national-institutes-of-health-announces-study-results-published-in-fnih 2024-09-11T22:35:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-foundation-for-the-national-institutes-of-health-announces-study-results-published-in-fnih 2024-09-11T22:35:39+00:00 weekly 0.7 https://trial.medpath.com/news/phase-3-trial-shows-superior-survival-with-rilertinib-for-egfr-mutated-nsclc 2024-09-11T22:29:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-3-trial-shows-superior-survival-with-rilertinib-for-egfr-mutated-nsclc 2024-09-11T22:29:44+00:00 weekly 0.7 https://trial.medpath.com/news/tremfya-r-guselkumab-receives-u-s-fda-approval-for-adults-with-moderately-to-pr-newswire 2024-09-11T22:23:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tremfya-r-guselkumab-receives-u-s-fda-approval-for-adults-with-moderately-to-pr-newswire 2024-09-11T22:23:07+00:00 weekly 0.7 https://trial.medpath.com/news/ascendis-pharma-receives-orphan-drug-exclusivity-in-the-u-s-for-yorvipath-morningstar 2024-09-11T22:22:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ascendis-pharma-receives-orphan-drug-exclusivity-in-the-u-s-for-yorvipath-morningstar 2024-09-11T22:22:02+00:00 weekly 0.7 https://trial.medpath.com/news/conventional-complementary-and-integrative-pain-therapies-in-a-military-population-with 2024-09-11T21:46:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/conventional-complementary-and-integrative-pain-therapies-in-a-military-population-with 2024-09-11T21:46:42+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-brain-mapping-tool-for-neuromodulation-therapies-parkinson-s-news-today 2024-09-11T21:16:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-clears-brain-mapping-tool-for-neuromodulation-therapies-parkinson-s-news-today 2024-09-11T21:16:13+00:00 weekly 0.7 https://trial.medpath.com/news/triluminate-update-teer-with-abbott-s-triclip-device-still-safe-effective-after-3-years 2024-09-11T21:13:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/triluminate-update-teer-with-abbott-s-triclip-device-still-safe-effective-after-3-years 2024-09-11T21:13:59+00:00 weekly 0.7 https://trial.medpath.com/news/norton-cancer-institute-patient-receives-first-in-world-clinical-trial-medicine-dos-louisville 2024-09-11T20:25:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/norton-cancer-institute-patient-receives-first-in-world-clinical-trial-medicine-dos-louisville 2024-09-11T20:25:55+00:00 weekly 0.7 https://trial.medpath.com/news/studies-show-safety-efficacy-of-rsv-preventive-drug-in-kids-cidrap 2024-09-11T20:25:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/studies-show-safety-efficacy-of-rsv-preventive-drug-in-kids-cidrap 2024-09-11T20:25:54+00:00 weekly 0.7 https://trial.medpath.com/news/biopharma-company-sues-dea-for-unjustified-delays-in-approving-cannabis-research 2024-09-11T20:05:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biopharma-company-sues-dea-for-unjustified-delays-in-approving-cannabis-research 2024-09-11T20:05:13+00:00 weekly 0.7 https://trial.medpath.com/news/dr-danilov-on-ongoing-mcl-clinical-trials-onclive 2024-09-11T19:57:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-danilov-on-ongoing-mcl-clinical-trials-onclive 2024-09-11T19:57:41+00:00 weekly 0.7 https://trial.medpath.com/news/expanding-possibilities-dana-farber-cancer-institute 2024-09-11T19:54:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/expanding-possibilities-dana-farber-cancer-institute 2024-09-11T19:54:11+00:00 weekly 0.7 https://trial.medpath.com/news/fda-reviewers-skeptical-of-ocaliva-for-rare-bile-duct-disease-medpage-today 2024-09-11T19:44:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-reviewers-skeptical-of-ocaliva-for-rare-bile-duct-disease-medpage-today 2024-09-11T19:44:25+00:00 weekly 0.7 https://trial.medpath.com/news/dedicated-trialist-nurse-navigators-help-advance-cancer-therapy-into-accelerated-approval 2024-09-11T19:25:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dedicated-trialist-nurse-navigators-help-advance-cancer-therapy-into-accelerated-approval 2024-09-11T19:25:26+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-510-k-clearance-to-under-mattress-device-that-assists-in-osa-diagnosis-healio 2024-09-11T19:16:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-510-k-clearance-to-under-mattress-device-that-assists-in-osa-diagnosis-healio 2024-09-11T19:16:34+00:00 weekly 0.7 https://trial.medpath.com/news/eortc-extends-medidata-partnership-to-help-power-new-phase-of-oncology-research 2024-09-11T18:54:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eortc-extends-medidata-partnership-to-help-power-new-phase-of-oncology-research 2024-09-11T18:54:13+00:00 weekly 0.7 https://trial.medpath.com/news/bria-imt-plus-checkpoint-inhibition-maintains-favorable-os-in-metastatic-breast-cancer 2024-09-11T18:44:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bria-imt-plus-checkpoint-inhibition-maintains-favorable-os-in-metastatic-breast-cancer 2024-09-11T18:44:56+00:00 weekly 0.7 https://trial.medpath.com/news/obesity-key-pipeline-developments-and-clinical-trial-insights-iqvia 2024-09-11T18:39:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/obesity-key-pipeline-developments-and-clinical-trial-insights-iqvia 2024-09-11T18:39:13+00:00 weekly 0.7 https://trial.medpath.com/news/mounjaro-expanded-to-include-weight-management-racgp 2024-09-11T18:02:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mounjaro-expanded-to-include-weight-management-racgp 2024-09-11T18:02:45+00:00 weekly 0.7 https://trial.medpath.com/news/basking-biosciences-doses-first-subject-in-phase-ii-acute-ischaemic-stroke-trial 2024-09-11T17:49:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/basking-biosciences-doses-first-subject-in-phase-ii-acute-ischaemic-stroke-trial 2024-09-11T17:49:57+00:00 weekly 0.7 https://trial.medpath.com/news/incendia-enrols-first-subject-in-phase-ic-advanced-solid-tumour-trial 2024-09-11T17:47:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/incendia-enrols-first-subject-in-phase-ic-advanced-solid-tumour-trial 2024-09-11T17:47:50+00:00 weekly 0.7 https://trial.medpath.com/news/china-boosts-regulatory-framework-for-local-pharmaceutical-manufacturing 2024-09-11T17:44:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/china-boosts-regulatory-framework-for-local-pharmaceutical-manufacturing 2024-09-11T17:44:44+00:00 weekly 0.7 https://trial.medpath.com/news/akebia-readies-launch-of-anemia-drug-vafseo-planning-talks-with-fda-on-pre-dialysis-use 2024-09-11T17:02:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/akebia-readies-launch-of-anemia-drug-vafseo-planning-talks-with-fda-on-pre-dialysis-use 2024-09-11T17:02:47+00:00 weekly 0.7 https://trial.medpath.com/news/a-new-fentanyl-vaccine-looks-promising-but-treating-drug-addiction-needs-a-more-complex 2024-09-11T16:24:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-new-fentanyl-vaccine-looks-promising-but-treating-drug-addiction-needs-a-more-complex 2024-09-11T16:24:25+00:00 weekly 0.7 https://trial.medpath.com/news/eu-clinical-trial-regulation-what-does-it-aim-to-achieve 2024-09-11T16:18:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eu-clinical-trial-regulation-what-does-it-aim-to-achieve 2024-09-11T16:18:40+00:00 weekly 0.7 https://trial.medpath.com/news/culturally-adapted-lifestyle-intervention-for-south-asian-adults-with-cardiovascular-risk-factors 2024-09-11T16:17:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/culturally-adapted-lifestyle-intervention-for-south-asian-adults-with-cardiovascular-risk-factors 2024-09-11T16:17:43+00:00 weekly 0.7 https://trial.medpath.com/news/diabetes-drug-helps-the-immune-system-recognize-reservoirs-of-hiv-study-discovers 2024-09-11T16:12:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/diabetes-drug-helps-the-immune-system-recognize-reservoirs-of-hiv-study-discovers 2024-09-11T16:12:54+00:00 weekly 0.7 https://trial.medpath.com/news/veligrotug-for-treatment-of-thyroid-eye-disease-meets-endpoints-in-phase-3-trial-healio 2024-09-11T16:04:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/veligrotug-for-treatment-of-thyroid-eye-disease-meets-endpoints-in-phase-3-trial-healio 2024-09-11T16:04:47+00:00 weekly 0.7 https://trial.medpath.com/news/actuate-receives-fda-orphan-drug-designation-for-elraglusib-for-treatment-of-soft-tissue 2024-09-11T15:51:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/actuate-receives-fda-orphan-drug-designation-for-elraglusib-for-treatment-of-soft-tissue 2024-09-11T15:51:03+00:00 weekly 0.7 https://trial.medpath.com/news/vla1553-chikungunya-virus-vaccine-shows-antibody-persistence-up-to-2-years-following 2024-09-11T15:47:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vla1553-chikungunya-virus-vaccine-shows-antibody-persistence-up-to-2-years-following 2024-09-11T15:47:14+00:00 weekly 0.7 https://trial.medpath.com/news/vaxxas-initiates-phase-i-clinical-trial-of-pre-pandemic-avian-influenza-a-virus-h7n9-biospace 2024-09-11T15:10:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vaxxas-initiates-phase-i-clinical-trial-of-pre-pandemic-avian-influenza-a-virus-h7n9-biospace 2024-09-11T15:10:18+00:00 weekly 0.7 https://trial.medpath.com/news/ultimovacs-announces-patient-recruitment-discontinuation-in-globenewswire 2024-09-11T15:09:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ultimovacs-announces-patient-recruitment-discontinuation-in-globenewswire 2024-09-11T15:09:34+00:00 weekly 0.7 https://trial.medpath.com/news/blood-cell-counts-have-unfairly-kept-black-and-middle-eastern-people-from-clinical-trials-study-says 2024-09-11T15:04:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/blood-cell-counts-have-unfairly-kept-black-and-middle-eastern-people-from-clinical-trials-study-says 2024-09-11T15:04:46+00:00 weekly 0.7 https://trial.medpath.com/news/vertex-crispr-s-casgevy-faces-complex-path-to-profitability-biospace 2024-09-11T15:03:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vertex-crispr-s-casgevy-faces-complex-path-to-profitability-biospace 2024-09-11T15:03:39+00:00 weekly 0.7 https://trial.medpath.com/news/adapt-a-clinical-trial-of-adaptive-treatment-for-early-smoking-cessation-relapse-uab 2024-09-11T15:01:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adapt-a-clinical-trial-of-adaptive-treatment-for-early-smoking-cessation-relapse-uab 2024-09-11T15:01:10+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-reports-data-from-phase-ii-nsclc-treatment-trial-clinical-trials-arena 2024-09-11T14:58:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/johnson-johnson-reports-data-from-phase-ii-nsclc-treatment-trial-clinical-trials-arena 2024-09-11T14:58:48+00:00 weekly 0.7 https://trial.medpath.com/news/sotatercept-gains-european-approval-for-pah-for-use-with-other-treatments 2024-09-11T14:57:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sotatercept-gains-european-approval-for-pah-for-use-with-other-treatments 2024-09-11T14:57:01+00:00 weekly 0.7 https://trial.medpath.com/news/merck-announces-positive-top-line-results-from-phase-3-trial-evaluating-efficacy-and 2024-09-11T14:52:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-announces-positive-top-line-results-from-phase-3-trial-evaluating-efficacy-and 2024-09-11T14:52:15+00:00 weekly 0.7 https://trial.medpath.com/news/entero-signs-letter-of-intent-to-license-and-commercialize-remote-patient-and-machine-vision 2024-09-11T14:30:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/entero-signs-letter-of-intent-to-license-and-commercialize-remote-patient-and-machine-vision 2024-09-11T14:30:36+00:00 weekly 0.7 https://trial.medpath.com/news/dcgi-suspends-entod-s-marketing-approval-for-presvu-eye-drops-amid-misuse-concerns 2024-09-11T14:24:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dcgi-suspends-entod-s-marketing-approval-for-presvu-eye-drops-amid-misuse-concerns 2024-09-11T14:24:02+00:00 weekly 0.7 https://trial.medpath.com/news/indies-pharma-gets-fda-approval-on-new-drug-jamaica-observer 2024-09-11T14:13:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/indies-pharma-gets-fda-approval-on-new-drug-jamaica-observer 2024-09-11T14:13:26+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-data-support-use-of-rpfviii-for-acquired-hemophilia-a-hcplive 2024-09-11T14:06:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/real-world-data-support-use-of-rpfviii-for-acquired-hemophilia-a-hcplive 2024-09-11T14:06:22+00:00 weekly 0.7 https://trial.medpath.com/news/sarepta-s-like-a-curse-on-me-fda-commissioner-califf-says-stat-news 2024-09-11T13:57:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sarepta-s-like-a-curse-on-me-fda-commissioner-califf-says-stat-news 2024-09-11T13:57:39+00:00 weekly 0.7 https://trial.medpath.com/news/mhra-authorization-of-dupixent-dupilumab-marks-a-significant-step-forward-as-the-uk 2024-09-11T13:53:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mhra-authorization-of-dupixent-dupilumab-marks-a-significant-step-forward-as-the-uk 2024-09-11T13:53:47+00:00 weekly 0.7 https://trial.medpath.com/news/tusamitamab-ravtansine-misses-survival-end-points-in-advanced-nsclc-trial-onclive 2024-09-11T13:34:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tusamitamab-ravtansine-misses-survival-end-points-in-advanced-nsclc-trial-onclive 2024-09-11T13:34:05+00:00 weekly 0.7 https://trial.medpath.com/news/pathologists-call-for-reform-in-her2-testing-standards-as-breast-cancer-treatment-landscape-evolves 2024-09-11T13:25:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pathologists-call-for-reform-in-her2-testing-standards-as-breast-cancer-treatment-landscape-evolves 2024-09-11T13:25:09+00:00 weekly 0.7 https://trial.medpath.com/news/enterprise-therapeutics-appoints-annabella-amatulli-as-head-of-regulatory-affairs 2024-09-11T13:18:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/enterprise-therapeutics-appoints-annabella-amatulli-as-head-of-regulatory-affairs 2024-09-11T13:18:07+00:00 weekly 0.7 https://trial.medpath.com/news/improving-lung-cancer-clinical-trial-design-tech-can-help-but-relationships-are-key 2024-09-11T13:15:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/improving-lung-cancer-clinical-trial-design-tech-can-help-but-relationships-are-key 2024-09-11T13:15:02+00:00 weekly 0.7 https://trial.medpath.com/news/pharmala-to-supply-johns-hopkins-medicine-for-clinical-trial-globenewswire 2024-09-11T13:05:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharmala-to-supply-johns-hopkins-medicine-for-clinical-trial-globenewswire 2024-09-11T13:05:31+00:00 weekly 0.7 https://trial.medpath.com/news/fda-gives-approval-for-duchenne-muscular-dystrophy-pediatric-treatment-science-2-0 2024-09-11T13:03:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-gives-approval-for-duchenne-muscular-dystrophy-pediatric-treatment-science-2-0 2024-09-11T13:03:06+00:00 weekly 0.7 https://trial.medpath.com/news/theradaptive-announces-first-patient-treated-in-oasis-clinical-trial-of 2024-09-11T13:00:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/theradaptive-announces-first-patient-treated-in-oasis-clinical-trial-of 2024-09-11T13:00:48+00:00 weekly 0.7 https://trial.medpath.com/news/comprehensive-cancer-research-from-dana-farber-to-lead-esmo-congress-2024 2024-09-11T12:43:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/comprehensive-cancer-research-from-dana-farber-to-lead-esmo-congress-2024 2024-09-11T12:43:38+00:00 weekly 0.7 https://trial.medpath.com/news/painreform-ltd-confirms-sutures-compatibility-in-human-clinical-trials-for-prf-110 2024-09-11T12:40:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/painreform-ltd-confirms-sutures-compatibility-in-human-clinical-trials-for-prf-110 2024-09-11T12:40:22+00:00 weekly 0.7 https://trial.medpath.com/news/ss-innovations-conducts-interactive-meeting-with-the-center-for-devices-and-yahoo-finance 2024-09-11T12:40:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ss-innovations-conducts-interactive-meeting-with-the-center-for-devices-and-yahoo-finance 2024-09-11T12:40:19+00:00 weekly 0.7 https://trial.medpath.com/news/allergan-aesthetics-launches-botox-r-cosmetic-onabotulinumtoxina-for-masseter 2024-09-11T12:33:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/allergan-aesthetics-launches-botox-r-cosmetic-onabotulinumtoxina-for-masseter 2024-09-11T12:33:49+00:00 weekly 0.7 https://trial.medpath.com/news/nuance-pharma-completes-recruitment-for-enhance-china-the-phase-3-clinical-trial-of 2024-09-11T12:03:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nuance-pharma-completes-recruitment-for-enhance-china-the-phase-3-clinical-trial-of 2024-09-11T12:03:22+00:00 weekly 0.7 https://trial.medpath.com/news/bio-thera-solutions-and-biogen-publish-phase-3-clinical-trial-data-for-tofidence 2024-09-11T12:01:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bio-thera-solutions-and-biogen-publish-phase-3-clinical-trial-data-for-tofidence 2024-09-11T12:01:05+00:00 weekly 0.7 https://trial.medpath.com/news/b-riley-raises-viridian-therapeutics-shares-target-on-phase-iii-thrive-study-investing-com 2024-09-11T11:51:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/b-riley-raises-viridian-therapeutics-shares-target-on-phase-iii-thrive-study-investing-com 2024-09-11T11:51:22+00:00 weekly 0.7 https://trial.medpath.com/news/searching-for-a-vaccine-against-east-coast-fever-tu-braunschweig-blogs 2024-09-11T11:26:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/searching-for-a-vaccine-against-east-coast-fever-tu-braunschweig-blogs 2024-09-11T11:26:03+00:00 weekly 0.7 https://trial.medpath.com/news/agios-announces-fda-orphan-drug-designation-granted-to-tebapivat-ag-946-for-stock-titan 2024-09-11T11:08:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/agios-announces-fda-orphan-drug-designation-granted-to-tebapivat-ag-946-for-stock-titan 2024-09-11T11:08:32+00:00 weekly 0.7 https://trial.medpath.com/news/sanofi-and-regeneron-s-dupixent-succeeds-in-trial-of-chronic-hives-stat-news 2024-09-11T11:02:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sanofi-and-regeneron-s-dupixent-succeeds-in-trial-of-chronic-hives-stat-news 2024-09-11T11:02:42+00:00 weekly 0.7 https://trial.medpath.com/news/viridian-therapeutics-stock-jumps-after-phase-iii-trial-met-all-endpoints-yahoo-finance 2024-09-11T10:57:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/viridian-therapeutics-stock-jumps-after-phase-iii-trial-met-all-endpoints-yahoo-finance 2024-09-11T10:57:48+00:00 weekly 0.7 https://trial.medpath.com/news/arch-biopartners-announces-alberta-health-services-approval-to-proceed-with-phase-ii-trial 2024-09-11T10:49:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/arch-biopartners-announces-alberta-health-services-approval-to-proceed-with-phase-ii-trial 2024-09-11T10:49:57+00:00 weekly 0.7 https://trial.medpath.com/news/patient-insights-into-the-decentralisation-of-clinical-trials-european-pharmaceutical-review 2024-09-11T10:44:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/patient-insights-into-the-decentralisation-of-clinical-trials-european-pharmaceutical-review 2024-09-11T10:44:50+00:00 weekly 0.7 https://trial.medpath.com/news/fda-rejects-mdma-treatment-for-ptsd-setbacks-and-new-directions-lexology 2024-09-11T10:16:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-rejects-mdma-treatment-for-ptsd-setbacks-and-new-directions-lexology 2024-09-11T10:16:18+00:00 weekly 0.7 https://trial.medpath.com/news/belantamab-mafodotin-pomalidomide-and-dexamethasone-for-triple-class-exposed-nature 2024-09-11T10:08:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/belantamab-mafodotin-pomalidomide-and-dexamethasone-for-triple-class-exposed-nature 2024-09-11T10:08:31+00:00 weekly 0.7 https://trial.medpath.com/news/praxis-stock-poised-for-growth-after-key-pipeline-progress-analyst-says-investing-com 2024-09-11T09:56:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/praxis-stock-poised-for-growth-after-key-pipeline-progress-analyst-says-investing-com 2024-09-11T09:56:17+00:00 weekly 0.7 https://trial.medpath.com/news/car-t-therapy-won-t-raise-odds-for-a-second-cancer-study-finds 2024-09-11T09:09:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/car-t-therapy-won-t-raise-odds-for-a-second-cancer-study-finds 2024-09-11T09:09:55+00:00 weekly 0.7 https://trial.medpath.com/news/daily-pill-helps-people-lose-weight-combines-glp-1-with-other-drug 2024-09-11T09:09:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/daily-pill-helps-people-lose-weight-combines-glp-1-with-other-drug 2024-09-11T09:09:21+00:00 weekly 0.7 https://trial.medpath.com/news/blood-test-could-gauge-your-odds-for-lung-trouble-like-copd 2024-09-11T09:09:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/blood-test-could-gauge-your-odds-for-lung-trouble-like-copd 2024-09-11T09:09:16+00:00 weekly 0.7 https://trial.medpath.com/news/sec-form-10-q-filed-by-engene-holdings-inc-quantisnow 2024-09-11T08:52:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sec-form-10-q-filed-by-engene-holdings-inc-quantisnow 2024-09-11T08:52:33+00:00 weekly 0.7 https://trial.medpath.com/news/prodrugs-and-patents-enhancing-therapy-adherence-and-reducing-side-effects 2024-09-11T08:09:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/prodrugs-and-patents-enhancing-therapy-adherence-and-reducing-side-effects 2024-09-11T08:09:05+00:00 weekly 0.7 https://trial.medpath.com/news/september-11-2024-harmonie-and-a-new-approach-to-commercial-clinical-trials-in 2024-09-11T08:06:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/september-11-2024-harmonie-and-a-new-approach-to-commercial-clinical-trials-in 2024-09-11T08:06:31+00:00 weekly 0.7 https://trial.medpath.com/news/never-give-up-treatment-breakthroughs-arrive-for-sclc-cure-today 2024-09-11T07:18:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/never-give-up-treatment-breakthroughs-arrive-for-sclc-cure-today 2024-09-11T07:18:15+00:00 weekly 0.7 https://trial.medpath.com/news/radiprodil-significantly-reduces-seizure-frequency-in-phase-1b-honeycomb-study-of 2024-09-11T07:10:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/radiprodil-significantly-reduces-seizure-frequency-in-phase-1b-honeycomb-study-of 2024-09-11T07:10:28+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-provides-update-on-phase-i-ii-therapeutic-herpes-simplex-virus-hsv-vaccine-trial 2024-09-11T06:03:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gsk-provides-update-on-phase-i-ii-therapeutic-herpes-simplex-virus-hsv-vaccine-trial 2024-09-11T06:03:53+00:00 weekly 0.7 https://trial.medpath.com/news/healthcare-discrimination-study-reveals-multiple-barriers-for-sickle-cell-disease-patients 2024-09-11T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/healthcare-discrimination-study-reveals-multiple-barriers-for-sickle-cell-disease-patients 2024-09-11T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bioversys-announces-strategic-investment-from-gibf2-and-launch-of-bv100-clinical 2024-09-11T05:46:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bioversys-announces-strategic-investment-from-gibf2-and-launch-of-bv100-clinical 2024-09-11T05:46:45+00:00 weekly 0.7 https://trial.medpath.com/news/press-release-dupixent-is-the-first-and-only-biologic-to-achieve-significant-improvements-in 2024-09-11T05:46:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/press-release-dupixent-is-the-first-and-only-biologic-to-achieve-significant-improvements-in 2024-09-11T05:46:44+00:00 weekly 0.7 https://trial.medpath.com/news/study-links-anti-ttg-and-ema-antibodies-to-fibromyalgia-risk-in-celiac-disease-patients 2024-09-11T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-links-anti-ttg-and-ema-antibodies-to-fibromyalgia-risk-in-celiac-disease-patients 2024-09-11T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/piflufolastat-18f-enters-commercial-market-in-spain-urology-times 2024-09-11T04:32:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/piflufolastat-18f-enters-commercial-market-in-spain-urology-times 2024-09-11T04:32:24+00:00 weekly 0.7 https://trial.medpath.com/news/investors-are-waking-up-to-centessa-s-sleepiness-drug-biopharma-dive 2024-09-11T04:15:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/investors-are-waking-up-to-centessa-s-sleepiness-drug-biopharma-dive 2024-09-11T04:15:49+00:00 weekly 0.7 https://trial.medpath.com/news/expert-reaction-to-conference-abstract-from-a-phase-1-study-on-safety-tolerability-and-weight 2024-09-11T04:12:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/expert-reaction-to-conference-abstract-from-a-phase-1-study-on-safety-tolerability-and-weight 2024-09-11T04:12:30+00:00 weekly 0.7 https://trial.medpath.com/news/study-reveals-significant-understaging-in-early-stage-pancreatic-cancer-diagnosis 2024-09-11T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-reveals-significant-understaging-in-early-stage-pancreatic-cancer-diagnosis 2024-09-11T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/roche-not-alarmed-by-obesity-drug-s-side-effects-r-d-head-says-swi-swissinfo-ch 2024-09-11T03:55:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/roche-not-alarmed-by-obesity-drug-s-side-effects-r-d-head-says-swi-swissinfo-ch 2024-09-11T03:55:39+00:00 weekly 0.7 https://trial.medpath.com/news/a-novo-nordisk-weight-loss-drug-lowers-bmi-in-kids-as-young-as-6-nbc-news 2024-09-11T02:15:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-novo-nordisk-weight-loss-drug-lowers-bmi-in-kids-as-young-as-6-nbc-news 2024-09-11T02:15:53+00:00 weekly 0.7 https://trial.medpath.com/news/novo-nordisk-experimental-obesity-pill-has-mild-to-moderate-side-effects-in-early-trial 2024-09-11T01:47:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novo-nordisk-experimental-obesity-pill-has-mild-to-moderate-side-effects-in-early-trial 2024-09-11T01:47:37+00:00 weekly 0.7 https://trial.medpath.com/news/skyhawk-therapeutics-to-present-additional-positive-topline-data-from-parts-a-and-b-of-phase-1-clinical-trial-of-sky-0515-at-european-huntington-s-disease-network-and-enroll-hd-2024 2024-09-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/skyhawk-therapeutics-to-present-additional-positive-topline-data-from-parts-a-and-b-of-phase-1-clinical-trial-of-sky-0515-at-european-huntington-s-disease-network-and-enroll-hd-2024 2024-09-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cellworks-biosimulation-platform-predicts-chemotherapy-benefit-in-nsclc-patients-beyond-pd-l1-status 2024-09-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cellworks-biosimulation-platform-predicts-chemotherapy-benefit-in-nsclc-patients-beyond-pd-l1-status 2024-09-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/highly-accurate-telix-s-phase-iii-zircon-trial-for-kidney-cancer-imaging-published-in-the 2024-09-10T22:48:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/highly-accurate-telix-s-phase-iii-zircon-trial-for-kidney-cancer-imaging-published-in-the 2024-09-10T22:48:29+00:00 weekly 0.7 https://trial.medpath.com/news/prophylactic-dexamethasone-regimen-reduces-infusion-related-globenewswire 2024-09-10T22:21:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/prophylactic-dexamethasone-regimen-reduces-infusion-related-globenewswire 2024-09-10T22:21:49+00:00 weekly 0.7 https://trial.medpath.com/news/walgreens-boots-alliance-inc-wba-td-cowen-9th-annual-futurehealth-conference-transcript 2024-09-10T22:16:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/walgreens-boots-alliance-inc-wba-td-cowen-9th-annual-futurehealth-conference-transcript 2024-09-10T22:16:20+00:00 weekly 0.7 https://trial.medpath.com/news/dr-leighl-on-patient-satisfaction-and-resource-utilization-from-paloma-3-in-nsclc 2024-09-10T22:04:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-leighl-on-patient-satisfaction-and-resource-utilization-from-paloma-3-in-nsclc 2024-09-10T22:04:57+00:00 weekly 0.7 https://trial.medpath.com/news/avistone-announces-results-from-a-sponsored-clinical-research-program-studying-morningstar 2024-09-10T21:56:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/avistone-announces-results-from-a-sponsored-clinical-research-program-studying-morningstar 2024-09-10T21:56:39+00:00 weekly 0.7 https://trial.medpath.com/news/easd-2024-cardiovascular-and-inflammatory-markers-reduce-after-orforglipron-treatment 2024-09-10T21:44:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/easd-2024-cardiovascular-and-inflammatory-markers-reduce-after-orforglipron-treatment 2024-09-10T21:44:51+00:00 weekly 0.7 https://trial.medpath.com/news/dexamethasone-reduces-infusion-related-reactions-in-patients-with-egfr-mutated-non-placera 2024-09-10T21:20:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dexamethasone-reduces-infusion-related-reactions-in-patients-with-egfr-mutated-non-placera 2024-09-10T21:20:44+00:00 weekly 0.7 https://trial.medpath.com/news/fda-action-update-august-2024-approvals-designations-and-clearances 2024-09-10T21:05:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-action-update-august-2024-approvals-designations-and-clearances 2024-09-10T21:05:56+00:00 weekly 0.7 https://trial.medpath.com/news/bridgebio-receives-fda-s-regenerative-medicine-advanced-therapy-rmat-designation 2024-09-10T20:50:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bridgebio-receives-fda-s-regenerative-medicine-advanced-therapy-rmat-designation 2024-09-10T20:50:48+00:00 weekly 0.7 https://trial.medpath.com/news/tofacitinib-effective-for-ankylosing-spondylitis-regardless-of-baseline-crp-level 2024-09-10T20:46:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tofacitinib-effective-for-ankylosing-spondylitis-regardless-of-baseline-crp-level 2024-09-10T20:46:45+00:00 weekly 0.7 https://trial.medpath.com/news/rate-of-cardiovascular-adverse-events-myocarditis-may-be-low-in-trials-assessing-icis 2024-09-10T20:06:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rate-of-cardiovascular-adverse-events-myocarditis-may-be-low-in-trials-assessing-icis 2024-09-10T20:06:57+00:00 weekly 0.7 https://trial.medpath.com/news/mirvetuximab-soravtansine-shows-efficacy-in-ovarian-cancer-despite-dose-adjustments 2024-09-10T19:09:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mirvetuximab-soravtansine-shows-efficacy-in-ovarian-cancer-despite-dose-adjustments 2024-09-10T19:09:19+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-510-k-clearance-to-sonic-incytes-velacur-r-determined-fat-fraction-vdff-a 2024-09-10T18:12:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-510-k-clearance-to-sonic-incytes-velacur-r-determined-fat-fraction-vdff-a 2024-09-10T18:12:19+00:00 weekly 0.7 https://trial.medpath.com/news/pan-covid-new-drug-sns812-achieves-superiority-in-phase-2-study-biospace 2024-09-10T17:55:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pan-covid-new-drug-sns812-achieves-superiority-in-phase-2-study-biospace 2024-09-10T17:55:43+00:00 weekly 0.7 https://trial.medpath.com/news/vasa-therapeutics-lead-drug-candidate-enters-clinical-trials-contract-pharma 2024-09-10T17:54:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vasa-therapeutics-lead-drug-candidate-enters-clinical-trials-contract-pharma 2024-09-10T17:54:04+00:00 weekly 0.7 https://trial.medpath.com/news/overcoming-failures-lessons-from-ipf-clinical-trials-in-the-past-year 2024-09-10T17:43:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/overcoming-failures-lessons-from-ipf-clinical-trials-in-the-past-year 2024-09-10T17:43:58+00:00 weekly 0.7 https://trial.medpath.com/news/dm-clinical-research-partners-with-brain-and-pain-care-and-sleep-care-clinic-for-new 2024-09-10T17:37:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dm-clinical-research-partners-with-brain-and-pain-care-and-sleep-care-clinic-for-new 2024-09-10T17:37:07+00:00 weekly 0.7 https://trial.medpath.com/news/phase-ii-study-of-taletrectinib-shows-clinically-meaningful-overall-response-and-prweb 2024-09-10T17:17:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-ii-study-of-taletrectinib-shows-clinically-meaningful-overall-response-and-prweb 2024-09-10T17:17:03+00:00 weekly 0.7 https://trial.medpath.com/news/atamyo-dion-foundation-partner-to-expand-lgmd-study-into-us 2024-09-10T17:15:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/atamyo-dion-foundation-partner-to-expand-lgmd-study-into-us 2024-09-10T17:15:32+00:00 weekly 0.7 https://trial.medpath.com/news/hope-vs-hype-seeking-truth-in-recent-prilenia-headlines-hdbuzz 2024-09-10T17:08:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hope-vs-hype-seeking-truth-in-recent-prilenia-headlines-hdbuzz 2024-09-10T17:08:35+00:00 weekly 0.7 https://trial.medpath.com/news/tackling-medchem-bias-one-functional-group-at-a-time 2024-09-10T17:04:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tackling-medchem-bias-one-functional-group-at-a-time 2024-09-10T17:04:02+00:00 weekly 0.7 https://trial.medpath.com/news/pridopidine-now-under-review-in-europe-as-huntington-s-treatment 2024-09-10T16:34:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pridopidine-now-under-review-in-europe-as-huntington-s-treatment 2024-09-10T16:34:52+00:00 weekly 0.7 https://trial.medpath.com/news/why-a-promising-breast-cancer-drug-doesn-t-work-and-how-to-improve-it 2024-09-10T16:14:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/why-a-promising-breast-cancer-drug-doesn-t-work-and-how-to-improve-it 2024-09-10T16:14:15+00:00 weekly 0.7 https://trial.medpath.com/news/patients-with-namd-successfully-switch-from-aflibercept-to-ranibizumab 2024-09-10T15:52:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/patients-with-namd-successfully-switch-from-aflibercept-to-ranibizumab 2024-09-10T15:52:48+00:00 weekly 0.7 https://trial.medpath.com/news/reflections-on-neonatal-erythropoietin-neuroprotection-studies-jama-network 2024-09-10T15:34:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/reflections-on-neonatal-erythropoietin-neuroprotection-studies-jama-network 2024-09-10T15:34:45+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-clearance-for-immunis-phase-ii-sarcopenic-obesity-trial-yahoo-finance 2024-09-10T15:14:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-clearance-for-immunis-phase-ii-sarcopenic-obesity-trial-yahoo-finance 2024-09-10T15:14:17+00:00 weekly 0.7 https://trial.medpath.com/news/leapfrog-bio-screens-clinical-stage-drugs-to-jump-into-cancer-markets 2024-09-10T15:11:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/leapfrog-bio-screens-clinical-stage-drugs-to-jump-into-cancer-markets 2024-09-10T15:11:05+00:00 weekly 0.7 https://trial.medpath.com/news/bayer-reports-encouraging-nsclc-drug-data-gets-approval-for-eylea-8mg 2024-09-10T15:03:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bayer-reports-encouraging-nsclc-drug-data-gets-approval-for-eylea-8mg 2024-09-10T15:03:38+00:00 weekly 0.7 https://trial.medpath.com/news/gene-therapy-for-inherited-retinal-dystrophy-shows-promise-inside-precision-medicine 2024-09-10T14:55:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gene-therapy-for-inherited-retinal-dystrophy-shows-promise-inside-precision-medicine 2024-09-10T14:55:10+00:00 weekly 0.7 https://trial.medpath.com/news/the-relationship-between-participant-diversity-and-dct-use-in-clinical-trials 2024-09-10T14:54:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-relationship-between-participant-diversity-and-dct-use-in-clinical-trials 2024-09-10T14:54:22+00:00 weekly 0.7 https://trial.medpath.com/news/telo-genomics-assessing-mrd-status-in-telo-dmrd-study-biospace 2024-09-10T14:46:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/telo-genomics-assessing-mrd-status-in-telo-dmrd-study-biospace 2024-09-10T14:46:00+00:00 weekly 0.7 https://trial.medpath.com/news/common-diabetes-drug-slows-growth-of-normal-cells-carrying-cancer-mutation-finds-study 2024-09-10T14:44:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/common-diabetes-drug-slows-growth-of-normal-cells-carrying-cancer-mutation-finds-study 2024-09-10T14:44:22+00:00 weekly 0.7 https://trial.medpath.com/news/incannex-healthcare-lands-60-million-financing-deal-green-market-report 2024-09-10T14:43:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/incannex-healthcare-lands-60-million-financing-deal-green-market-report 2024-09-10T14:43:04+00:00 weekly 0.7 https://trial.medpath.com/news/uk-study-lifetime-statin-therapy-proves-cost-effective-for-seniors-regardless-of-cvd-history 2024-09-10T14:30:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uk-study-lifetime-statin-therapy-proves-cost-effective-for-seniors-regardless-of-cvd-history 2024-09-10T14:30:48+00:00 weekly 0.7 https://trial.medpath.com/news/roivant-creates-new-vant-to-license-bayer-s-pulmonary-hypertension-drug-biospace 2024-09-10T14:22:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/roivant-creates-new-vant-to-license-bayer-s-pulmonary-hypertension-drug-biospace 2024-09-10T14:22:59+00:00 weekly 0.7 https://trial.medpath.com/news/buy-rating-justified-for-iterum-therapeutics-amid-anticipated-fda-approval-of-sulopenem-for-uutis 2024-09-10T14:10:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/buy-rating-justified-for-iterum-therapeutics-amid-anticipated-fda-approval-of-sulopenem-for-uutis 2024-09-10T14:10:42+00:00 weekly 0.7 https://trial.medpath.com/news/oncohost-accepted-to-present-poster-demonstrating-prophet-r-s-application-in-renal-cell 2024-09-10T14:10:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oncohost-accepted-to-present-poster-demonstrating-prophet-r-s-application-in-renal-cell 2024-09-10T14:10:26+00:00 weekly 0.7 https://trial.medpath.com/news/verona-pharma-a-post-fda-approval-analysis-nasdaq-vrna-seeking-alpha 2024-09-10T14:09:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/verona-pharma-a-post-fda-approval-analysis-nasdaq-vrna-seeking-alpha 2024-09-10T14:09:33+00:00 weekly 0.7 https://trial.medpath.com/news/travere-therapeutics-stock-target-boosted-buy-rating-held-on-fda-approval-investing-com 2024-09-10T13:58:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/travere-therapeutics-stock-target-boosted-buy-rating-held-on-fda-approval-investing-com 2024-09-10T13:58:42+00:00 weekly 0.7 https://trial.medpath.com/news/five-biotech-news-stories-you-need-to-read-today 2024-09-10T13:31:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/five-biotech-news-stories-you-need-to-read-today 2024-09-10T13:31:43+00:00 weekly 0.7 https://trial.medpath.com/news/zokinvy-lonafarnib-the-only-fda-approved-treatment-for-hutchinson-gilford-progeria 2024-09-10T13:27:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zokinvy-lonafarnib-the-only-fda-approved-treatment-for-hutchinson-gilford-progeria 2024-09-10T13:27:19+00:00 weekly 0.7 https://trial.medpath.com/news/daewoong-pharmaceutical-secures-ind-approval-for-dissolvable-microneedle-growth-hormone-patch 2024-09-10T13:17:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/daewoong-pharmaceutical-secures-ind-approval-for-dissolvable-microneedle-growth-hormone-patch 2024-09-10T13:17:38+00:00 weekly 0.7 https://trial.medpath.com/news/know-your-tumor-uncovers-rare-mutation-leads-to-effective-treatment-for-patient 2024-09-10T13:04:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/know-your-tumor-uncovers-rare-mutation-leads-to-effective-treatment-for-patient 2024-09-10T13:04:20+00:00 weekly 0.7 https://trial.medpath.com/news/hyperbaric-oxygen-therapy-for-ulcerative-colitis-inventum-university-of-miami 2024-09-10T13:02:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hyperbaric-oxygen-therapy-for-ulcerative-colitis-inventum-university-of-miami 2024-09-10T13:02:11+00:00 weekly 0.7 https://trial.medpath.com/news/robert-duggan-wins-again-as-summit-lung-cancer-treatment-beats-keytruda-stat-news 2024-09-10T12:45:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/robert-duggan-wins-again-as-summit-lung-cancer-treatment-beats-keytruda-stat-news 2024-09-10T12:45:05+00:00 weekly 0.7 https://trial.medpath.com/news/corvus-pharmaceuticals-initiates-registrational-phase-3-clinical-trial-of-soquelitinib-for 2024-09-10T12:34:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/corvus-pharmaceuticals-initiates-registrational-phase-3-clinical-trial-of-soquelitinib-for 2024-09-10T12:34:53+00:00 weekly 0.7 https://trial.medpath.com/news/new-secondary-analysis-of-phase-3-data-demonstrates-sotagliflozin-improves-time-in 2024-09-10T12:30:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-secondary-analysis-of-phase-3-data-demonstrates-sotagliflozin-improves-time-in 2024-09-10T12:30:15+00:00 weekly 0.7 https://trial.medpath.com/news/boehringer-ingelheim-reports-positive-results-from-trial-of-her2-lung-cancer-drug 2024-09-10T12:27:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/boehringer-ingelheim-reports-positive-results-from-trial-of-her2-lung-cancer-drug 2024-09-10T12:27:44+00:00 weekly 0.7 https://trial.medpath.com/news/integrative-radiopathomics-model-for-predicting-progression-free-survival-in-patients-with 2024-09-10T12:25:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/integrative-radiopathomics-model-for-predicting-progression-free-survival-in-patients-with 2024-09-10T12:25:00+00:00 weekly 0.7 https://trial.medpath.com/news/man-with-incurable-cancer-among-first-to-undergo-ground-breaking-new-treatment-stv-news 2024-09-10T12:23:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/man-with-incurable-cancer-among-first-to-undergo-ground-breaking-new-treatment-stv-news 2024-09-10T12:23:13+00:00 weekly 0.7 https://trial.medpath.com/news/could-a-pill-help-ease-sleep-apnea 2024-09-10T12:15:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/could-a-pill-help-ease-sleep-apnea 2024-09-10T12:15:36+00:00 weekly 0.7 https://trial.medpath.com/news/halia-therapeutics-to-present-an-update-on-phase-ii-clinical-trial-data-of-ht-6184-pr-newswire 2024-09-10T12:15:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/halia-therapeutics-to-present-an-update-on-phase-ii-clinical-trial-data-of-ht-6184-pr-newswire 2024-09-10T12:15:06+00:00 weekly 0.7 https://trial.medpath.com/news/reveal-genomics-r-announces-positive-top-line-results-for-her2dx-r-in-cleopatra 2024-09-10T12:14:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/reveal-genomics-r-announces-positive-top-line-results-for-her2dx-r-in-cleopatra 2024-09-10T12:14:31+00:00 weekly 0.7 https://trial.medpath.com/news/belite-bio-announces-first-patient-dosed-in-phase-2-3-dragon-ii-trial-of-tinlarebant-for 2024-09-10T12:07:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/belite-bio-announces-first-patient-dosed-in-phase-2-3-dragon-ii-trial-of-tinlarebant-for 2024-09-10T12:07:25+00:00 weekly 0.7 https://trial.medpath.com/news/academic-community-collaboration-improves-multiple-myeloma-treatment-outcomes-experts-report 2024-09-10T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/academic-community-collaboration-improves-multiple-myeloma-treatment-outcomes-experts-report 2024-09-10T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/regeneron-s-libtayo-shows-durable-survival-benefits-in-phase-3-lung-cancer-study 2024-09-10T11:45:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/regeneron-s-libtayo-shows-durable-survival-benefits-in-phase-3-lung-cancer-study 2024-09-10T11:45:39+00:00 weekly 0.7 https://trial.medpath.com/news/quralis-doses-first-participant-cohort-in-phase-1-multiple-ascending-dose-mad-clinical 2024-09-10T11:45:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/quralis-doses-first-participant-cohort-in-phase-1-multiple-ascending-dose-mad-clinical 2024-09-10T11:45:39+00:00 weekly 0.7 https://trial.medpath.com/news/europe-sidelines-alzheimer-s-drug-lessons-must-be-learnt-nature 2024-09-10T11:45:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/europe-sidelines-alzheimer-s-drug-lessons-must-be-learnt-nature 2024-09-10T11:45:31+00:00 weekly 0.7 https://trial.medpath.com/news/cardiol-therapeutics-announces-completion-of-the-maveric-phase-ii-study-in-recurrent 2024-09-10T11:40:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cardiol-therapeutics-announces-completion-of-the-maveric-phase-ii-study-in-recurrent 2024-09-10T11:40:18+00:00 weekly 0.7 https://trial.medpath.com/news/delta-fly-pharma-inc-phase-i-ii-combo-study-of-dfp-10917-with-venetoclax-in-patients 2024-09-10T11:33:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/delta-fly-pharma-inc-phase-i-ii-combo-study-of-dfp-10917-with-venetoclax-in-patients 2024-09-10T11:33:16+00:00 weekly 0.7 https://trial.medpath.com/news/zydus-lifesciences-completes-phase-iia-trial-of-usnoflast-in-als-patients-cnbc-tv18 2024-09-10T11:27:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zydus-lifesciences-completes-phase-iia-trial-of-usnoflast-in-als-patients-cnbc-tv18 2024-09-10T11:27:02+00:00 weekly 0.7 https://trial.medpath.com/news/silo-pharma-announces-completion-of-fda-pre-ind-meeting-to-advance-development-of 2024-09-10T11:07:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/silo-pharma-announces-completion-of-fda-pre-ind-meeting-to-advance-development-of 2024-09-10T11:07:11+00:00 weekly 0.7 https://trial.medpath.com/news/kalvista-pharmaceuticals-to-participate-in-the-2024-cantor-global-healthcare-conference 2024-09-10T11:06:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kalvista-pharmaceuticals-to-participate-in-the-2024-cantor-global-healthcare-conference 2024-09-10T11:06:30+00:00 weekly 0.7 https://trial.medpath.com/news/media-update-ers-dupixent-data-reinforce-clinically-meaningful-benefit-from-pooled 2024-09-10T10:40:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/media-update-ers-dupixent-data-reinforce-clinically-meaningful-benefit-from-pooled 2024-09-10T10:40:54+00:00 weekly 0.7 https://trial.medpath.com/news/phase-2-predict-ild-imaging-study-commences-in-interstitial-lung-disease-pharmatimes 2024-09-10T10:34:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-2-predict-ild-imaging-study-commences-in-interstitial-lung-disease-pharmatimes 2024-09-10T10:34:12+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-shares-fall-5-on-disappointing-lung-cancer-drug-trial-results-cnbc 2024-09-10T10:15:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-shares-fall-5-on-disappointing-lung-cancer-drug-trial-results-cnbc 2024-09-10T10:15:18+00:00 weekly 0.7 https://trial.medpath.com/news/tc-biopharm-announces-plans-for-monkey-pox-treatment-studies 2024-09-10T10:09:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tc-biopharm-announces-plans-for-monkey-pox-treatment-studies 2024-09-10T10:09:21+00:00 weekly 0.7 https://trial.medpath.com/news/updated-data-from-phase-ii-clinical-trial-of-iruplinalkib-tablets-qixinke-r-presented-at 2024-09-10T10:06:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/updated-data-from-phase-ii-clinical-trial-of-iruplinalkib-tablets-qixinke-r-presented-at 2024-09-10T10:06:03+00:00 weekly 0.7 https://trial.medpath.com/news/maia-biotechnology-announces-positive-survival-updates-in-phase-2-study-of-thio-in-non 2024-09-10T10:04:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/maia-biotechnology-announces-positive-survival-updates-in-phase-2-study-of-thio-in-non 2024-09-10T10:04:12+00:00 weekly 0.7 https://trial.medpath.com/news/global-exosome-market-size-forecast-trials-and-trends-globenewswire 2024-09-10T09:43:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/global-exosome-market-size-forecast-trials-and-trends-globenewswire 2024-09-10T09:43:59+00:00 weekly 0.7 https://trial.medpath.com/news/libido-can-drop-after-menopause-but-this-therapy-can-help 2024-09-10T09:09:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/libido-can-drop-after-menopause-but-this-therapy-can-help 2024-09-10T09:09:33+00:00 weekly 0.7 https://trial.medpath.com/news/us-fda-advisors-want-iterum-s-antibiotic-indication-narrowed-pink-sheet-citeline 2024-09-10T09:07:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/us-fda-advisors-want-iterum-s-antibiotic-indication-narrowed-pink-sheet-citeline 2024-09-10T09:07:17+00:00 weekly 0.7 https://trial.medpath.com/news/expert-challenges-benign-classification-of-gleason-6-prostate-cancer-emphasizes-need-for-comprehensive-assessment 2024-09-10T08:56:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/expert-challenges-benign-classification-of-gleason-6-prostate-cancer-emphasizes-need-for-comprehensive-assessment 2024-09-10T08:56:53+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-says-lung-cancer-drug-trial-shows-no-significant-improvement-in-overall-survival 2024-09-10T08:32:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-says-lung-cancer-drug-trial-shows-no-significant-improvement-in-overall-survival 2024-09-10T08:32:37+00:00 weekly 0.7 https://trial.medpath.com/news/study-links-testosterone-to-heightened-covid-19-severity-in-men-through-immune-response-modulation 2024-09-10T06:58:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-links-testosterone-to-heightened-covid-19-severity-in-men-through-immune-response-modulation 2024-09-10T06:58:09+00:00 weekly 0.7 https://trial.medpath.com/news/the-airpods-pro-2-will-soon-double-as-hearing-aids-the-verge 2024-09-10T06:36:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-airpods-pro-2-will-soon-double-as-hearing-aids-the-verge 2024-09-10T06:36:29+00:00 weekly 0.7 https://trial.medpath.com/news/first-patient-enters-dmx-200-open-label-extension-study-after-successfully-completing 2024-09-10T06:20:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-patient-enters-dmx-200-open-label-extension-study-after-successfully-completing 2024-09-10T06:20:14+00:00 weekly 0.7 https://trial.medpath.com/news/ose-immunotherapeutics-announces-global-launch-of-artemia-phase-3-registration-study 2024-09-10T06:12:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ose-immunotherapeutics-announces-global-launch-of-artemia-phase-3-registration-study 2024-09-10T06:12:10+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approval-for-sickle-cell-disease-gene-therapy-medical-news-bulletin 2024-09-10T06:01:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approval-for-sickle-cell-disease-gene-therapy-medical-news-bulletin 2024-09-10T06:01:26+00:00 weekly 0.7 https://trial.medpath.com/news/non-small-cell-lung-cancer-nsclc-clinical-trials-2024-ema-openpr-com 2024-09-10T05:50:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/non-small-cell-lung-cancer-nsclc-clinical-trials-2024-ema-openpr-com 2024-09-10T05:50:56+00:00 weekly 0.7 https://trial.medpath.com/news/hs-20093-generates-responses-in-pretreated-es-sclc-onclive 2024-09-10T05:17:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hs-20093-generates-responses-in-pretreated-es-sclc-onclive 2024-09-10T05:17:20+00:00 weekly 0.7 https://trial.medpath.com/news/novel-proteomics-test-prophet-shows-promise-in-guiding-lung-cancer-immunotherapy-decisions 2024-09-10T05:00:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-proteomics-test-prophet-shows-promise-in-guiding-lung-cancer-immunotherapy-decisions 2024-09-10T05:00:35+00:00 weekly 0.7 https://trial.medpath.com/news/closing-the-gender-diagnostic-gap-with-a-sample-collecting-tampon 2024-09-10T05:00:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/closing-the-gender-diagnostic-gap-with-a-sample-collecting-tampon 2024-09-10T05:00:06+00:00 weekly 0.7 https://trial.medpath.com/news/biotron-updates-on-bit225-012-phase-2-covid-19-clinical-trial-biotech-dispatch 2024-09-10T02:38:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biotron-updates-on-bit225-012-phase-2-covid-19-clinical-trial-biotech-dispatch 2024-09-10T02:38:27+00:00 weekly 0.7 https://trial.medpath.com/news/zongertinib-yields-meaningful-responses-in-pretreated-her2-mutated-nsclc 2024-09-10T02:22:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zongertinib-yields-meaningful-responses-in-pretreated-her2-mutated-nsclc 2024-09-10T02:22:11+00:00 weekly 0.7 https://trial.medpath.com/news/type-1-diabetes-uab-startup-gains-fda-clearance-to-test-novel-oral-drug-the-alabama 2024-09-10T02:02:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/type-1-diabetes-uab-startup-gains-fda-clearance-to-test-novel-oral-drug-the-alabama 2024-09-10T02:02:32+00:00 weekly 0.7 https://trial.medpath.com/news/innovent-delivers-oral-presentation-of-updated-results-from-a-pivotal-phase-2-pr-newswire 2024-09-10T01:23:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/innovent-delivers-oral-presentation-of-updated-results-from-a-pivotal-phase-2-pr-newswire 2024-09-10T01:23:45+00:00 weekly 0.7 https://trial.medpath.com/news/sacituzumab-govitecan-generates-responses-with-manageable-safety-profile-in-es-sclc 2024-09-10T01:01:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sacituzumab-govitecan-generates-responses-with-manageable-safety-profile-in-es-sclc 2024-09-10T01:01:55+00:00 weekly 0.7 https://trial.medpath.com/news/how-daratumumab-sc-is-being-perceived-versus-the-iv-form-ppa-dove-medical-press 2024-09-10T00:58:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/how-daratumumab-sc-is-being-perceived-versus-the-iv-form-ppa-dove-medical-press 2024-09-10T00:58:41+00:00 weekly 0.7 https://trial.medpath.com/news/oxford-scientists-develop-first-cancer-prevention-vaccine-for-lynch-syndrome-patients 2024-09-10T00:01:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oxford-scientists-develop-first-cancer-prevention-vaccine-for-lynch-syndrome-patients 2024-09-10T00:01:46+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-in-parkinson-s-treatment-personalized-deep-brain-stimulation 2024-09-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-in-parkinson-s-treatment-personalized-deep-brain-stimulation 2024-09-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-evidence-shows-apixaban-reduces-major-bleeding-risk-compared-to-rivaroxaban-in-atrial-fibrillation-patients 2024-09-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/real-world-evidence-shows-apixaban-reduces-major-bleeding-risk-compared-to-rivaroxaban-in-atrial-fibrillation-patients 2024-09-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eu-chmp-opinions-and-maa-updates-citeline-news-insights 2024-09-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eu-chmp-opinions-and-maa-updates-citeline-news-insights 2024-09-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bevacizumab-addition-to-first-line-chemotherapy-shows-real-world-benefit-in-high-risk-ovarian-cancer 2024-09-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bevacizumab-addition-to-first-line-chemotherapy-shows-real-world-benefit-in-high-risk-ovarian-cancer 2024-09-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/phanes-therapeutics-announces-first-patient-dosed-in-clinical-study-of-pt886-in 2024-09-09T23:52:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phanes-therapeutics-announces-first-patient-dosed-in-clinical-study-of-pt886-in 2024-09-09T23:52:51+00:00 weekly 0.7 https://trial.medpath.com/news/who-still-benefits-from-paxlovid-idsa 2024-09-09T23:38:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/who-still-benefits-from-paxlovid-idsa 2024-09-09T23:38:25+00:00 weekly 0.7 https://trial.medpath.com/news/medicinova-announces-abstract-regarding-mn-166-ibudilast-in-combat-als-clinical 2024-09-09T23:22:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medicinova-announces-abstract-regarding-mn-166-ibudilast-in-combat-als-clinical 2024-09-09T23:22:07+00:00 weekly 0.7 https://trial.medpath.com/news/withings-sleep-rx-receives-fda-clearance-for-home-sleep-apnea-testing 2024-09-09T23:03:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/withings-sleep-rx-receives-fda-clearance-for-home-sleep-apnea-testing 2024-09-09T23:03:49+00:00 weekly 0.7 https://trial.medpath.com/news/sleep-apnea-detection-will-be-on-apple-watches-soon-here-s-how-it-will-work-cnet 2024-09-09T22:54:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sleep-apnea-detection-will-be-on-apple-watches-soon-here-s-how-it-will-work-cnet 2024-09-09T22:54:45+00:00 weekly 0.7 https://trial.medpath.com/news/analysis-further-shows-perioperative-pembrolizumab-efficacy-in-early-stage-nsclc 2024-09-09T22:01:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/analysis-further-shows-perioperative-pembrolizumab-efficacy-in-early-stage-nsclc 2024-09-09T22:01:16+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-deepwell-digital-therapeutics-software-development-kit-massdevice 2024-09-09T21:32:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-clears-deepwell-digital-therapeutics-software-development-kit-massdevice 2024-09-09T21:32:54+00:00 weekly 0.7 https://trial.medpath.com/news/study-compares-dose-escalation-with-biologics-in-psoriasis-dermatology-times 2024-09-09T21:12:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-compares-dose-escalation-with-biologics-in-psoriasis-dermatology-times 2024-09-09T21:12:19+00:00 weekly 0.7 https://trial.medpath.com/news/aumolertinib-improves-pfs-in-unresectable-stage-iii-egfr-nsclc-after-chemoradiotherapy 2024-09-09T20:52:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aumolertinib-improves-pfs-in-unresectable-stage-iii-egfr-nsclc-after-chemoradiotherapy 2024-09-09T20:52:49+00:00 weekly 0.7 https://trial.medpath.com/news/eyen-shares-are-trading-higher-today-what-you-need-to-know-benzinga 2024-09-09T20:20:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eyen-shares-are-trading-higher-today-what-you-need-to-know-benzinga 2024-09-09T20:20:52+00:00 weekly 0.7 https://trial.medpath.com/news/solid-biosciences-tracking-long-term-effects-of-duchenne-muscular-dystrophy-gene 2024-09-09T20:15:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/solid-biosciences-tracking-long-term-effects-of-duchenne-muscular-dystrophy-gene 2024-09-09T20:15:16+00:00 weekly 0.7 https://trial.medpath.com/news/vir-biotechnology-announces-closing-of-exclusive-worldwide-license-agreement-with 2024-09-09T20:10:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vir-biotechnology-announces-closing-of-exclusive-worldwide-license-agreement-with 2024-09-09T20:10:14+00:00 weekly 0.7 https://trial.medpath.com/news/nivolumab-plus-chemotherapy-extends-survival-in-lymph-node-only-metastatic-urothelial-cancer 2024-09-09T19:13:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nivolumab-plus-chemotherapy-extends-survival-in-lymph-node-only-metastatic-urothelial-cancer 2024-09-09T19:13:13+00:00 weekly 0.7 https://trial.medpath.com/news/pembrolizumab-plus-ccrt-scores-in-east-asian-subgroup-with-cervical-cancer 2024-09-09T19:11:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pembrolizumab-plus-ccrt-scores-in-east-asian-subgroup-with-cervical-cancer 2024-09-09T19:11:58+00:00 weekly 0.7 https://trial.medpath.com/news/stealth-biotherapeutics-announces-fda-advisory-committee-meeting-to-review-biospace 2024-09-09T19:11:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/stealth-biotherapeutics-announces-fda-advisory-committee-meeting-to-review-biospace 2024-09-09T19:11:45+00:00 weekly 0.7 https://trial.medpath.com/news/bay-2927088-displays-durable-responses-in-her2-mutated-nsclc-onclive 2024-09-09T19:03:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bay-2927088-displays-durable-responses-in-her2-mutated-nsclc-onclive 2024-09-09T19:03:15+00:00 weekly 0.7 https://trial.medpath.com/news/phase-ii-study-for-sjogren-s-syndrome-drug-cooperation-between-servier-than-and-clariness 2024-09-09T18:50:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-ii-study-for-sjogren-s-syndrome-drug-cooperation-between-servier-than-and-clariness 2024-09-09T18:50:55+00:00 weekly 0.7 https://trial.medpath.com/news/brigham-led-study-finds-weight-loss-drug-semaglutide-reduced-covid-19-related 2024-09-09T18:29:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/brigham-led-study-finds-weight-loss-drug-semaglutide-reduced-covid-19-related 2024-09-09T18:29:06+00:00 weekly 0.7 https://trial.medpath.com/news/agenus-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses-morningstar 2024-09-09T18:28:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/agenus-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses-morningstar 2024-09-09T18:28:49+00:00 weekly 0.7 https://trial.medpath.com/news/study-olezarsen-effective-treatment-for-high-triglycerides-mass-general-brigham 2024-09-09T18:20:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-olezarsen-effective-treatment-for-high-triglycerides-mass-general-brigham 2024-09-09T18:20:54+00:00 weekly 0.7 https://trial.medpath.com/news/psilocybin-drug-by-psilera-could-treat-frontotemporal-dementia-without-psychoactive-effects 2024-09-09T18:20:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/psilocybin-drug-by-psilera-could-treat-frontotemporal-dementia-without-psychoactive-effects 2024-09-09T18:20:11+00:00 weekly 0.7 https://trial.medpath.com/news/md-anderson-research-highlights-special-edition-2-newswise 2024-09-09T18:11:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/md-anderson-research-highlights-special-edition-2-newswise 2024-09-09T18:11:55+00:00 weekly 0.7 https://trial.medpath.com/news/the-changing-landscape-of-clinical-trials-in-cancer-care-oncology-nursing-news 2024-09-09T18:11:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-changing-landscape-of-clinical-trials-in-cancer-care-oncology-nursing-news 2024-09-09T18:11:33+00:00 weekly 0.7 https://trial.medpath.com/news/directrx-pharmacy-distributing-copd-therapy-ohtuvayre-in-us 2024-09-09T17:53:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/directrx-pharmacy-distributing-copd-therapy-ohtuvayre-in-us 2024-09-09T17:53:33+00:00 weekly 0.7 https://trial.medpath.com/news/biorationality-fda-clarification-provides-new-indications-and-process-change-for-biosimilars 2024-09-09T17:05:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biorationality-fda-clarification-provides-new-indications-and-process-change-for-biosimilars 2024-09-09T17:05:48+00:00 weekly 0.7 https://trial.medpath.com/news/phase-3-charm-results-highlight-potential-of-iv-glibenclamide-to-improve-independent 2024-09-09T17:04:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-3-charm-results-highlight-potential-of-iv-glibenclamide-to-improve-independent 2024-09-09T17:04:56+00:00 weekly 0.7 https://trial.medpath.com/news/advancing-hope-udaily-university-of-delaware 2024-09-09T16:54:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/advancing-hope-udaily-university-of-delaware 2024-09-09T16:54:13+00:00 weekly 0.7 https://trial.medpath.com/news/rdca-dap-nets-new-data-to-speed-research-therapies-for-cf-cystic-fibrosis-news-today 2024-09-09T16:42:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rdca-dap-nets-new-data-to-speed-research-therapies-for-cf-cystic-fibrosis-news-today 2024-09-09T16:42:51+00:00 weekly 0.7 https://trial.medpath.com/news/fda-letter-supports-use-of-new-alpha-synuclein-assay-in-trials-parkinson-s-news-today 2024-09-09T16:42:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-letter-supports-use-of-new-alpha-synuclein-assay-in-trials-parkinson-s-news-today 2024-09-09T16:42:41+00:00 weekly 0.7 https://trial.medpath.com/news/iu-research-targets-debilitating-side-effects-for-black-breast-cancer-patients 2024-09-09T16:27:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/iu-research-targets-debilitating-side-effects-for-black-breast-cancer-patients 2024-09-09T16:27:22+00:00 weekly 0.7 https://trial.medpath.com/news/a-better-fix-for-food-allergies-the-atlantic 2024-09-09T15:31:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-better-fix-for-food-allergies-the-atlantic 2024-09-09T15:31:24+00:00 weekly 0.7 https://trial.medpath.com/news/pierre-fabre-laboratories-receives-european-commission-approval-for-braftovi 2024-09-09T15:31:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pierre-fabre-laboratories-receives-european-commission-approval-for-braftovi 2024-09-09T15:31:13+00:00 weekly 0.7 https://trial.medpath.com/news/zealand-pharma-announces-positive-topline-results-from-13-week-phase-1b-multiple-quantisnow 2024-09-09T15:21:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zealand-pharma-announces-positive-topline-results-from-13-week-phase-1b-multiple-quantisnow 2024-09-09T15:21:20+00:00 weekly 0.7 https://trial.medpath.com/news/early-metabolic-profiling-could-identify-babies-at-risk-of-sids-inside-precision-medicine 2024-09-09T15:04:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/early-metabolic-profiling-could-identify-babies-at-risk-of-sids-inside-precision-medicine 2024-09-09T15:04:37+00:00 weekly 0.7 https://trial.medpath.com/news/the-highly-anticipated-fda-approvals-of-galderma-s-nemolizumab-and-eli-lilly-s-markets-insider 2024-09-09T14:55:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-highly-anticipated-fda-approvals-of-galderma-s-nemolizumab-and-eli-lilly-s-markets-insider 2024-09-09T14:55:55+00:00 weekly 0.7 https://trial.medpath.com/news/a-diagnosis-of-triple-negative-breast-cancer-was-not-on-my-radar-the-asco-post 2024-09-09T14:51:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-diagnosis-of-triple-negative-breast-cancer-was-not-on-my-radar-the-asco-post 2024-09-09T14:51:50+00:00 weekly 0.7 https://trial.medpath.com/news/dow-jones-today-major-indexes-higher-as-stocks-look-to-rebound-from-biggest-weekly 2024-09-09T14:51:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dow-jones-today-major-indexes-higher-as-stocks-look-to-rebound-from-biggest-weekly 2024-09-09T14:51:29+00:00 weekly 0.7 https://trial.medpath.com/news/grail-s-potential-turnaround-seeking-fda-approval-for-galleri-nasdaq-gral 2024-09-09T14:51:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/grail-s-potential-turnaround-seeking-fda-approval-for-galleri-nasdaq-gral 2024-09-09T14:51:06+00:00 weekly 0.7 https://trial.medpath.com/news/tubeless-insulin-patch-pump-receives-fda-clearance-for-type-1-and-type-2-diabetes-healio 2024-09-09T14:48:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tubeless-insulin-patch-pump-receives-fda-clearance-for-type-1-and-type-2-diabetes-healio 2024-09-09T14:48:54+00:00 weekly 0.7 https://trial.medpath.com/news/zeroing-in-on-vaginal-microbes-that-most-increase-hiv-risk-fred-hutchinson-cancer-center 2024-09-09T14:45:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zeroing-in-on-vaginal-microbes-that-most-increase-hiv-risk-fred-hutchinson-cancer-center 2024-09-09T14:45:32+00:00 weekly 0.7 https://trial.medpath.com/news/earnings-call-genus-reports-progress-amid-market-challenges-eyes-fda-approval 2024-09-09T14:27:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/earnings-call-genus-reports-progress-amid-market-challenges-eyes-fda-approval 2024-09-09T14:27:26+00:00 weekly 0.7 https://trial.medpath.com/news/avacta-to-present-updated-clinical-data-on-ava6000-at-the-european-society-for-medical 2024-09-09T14:25:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/avacta-to-present-updated-clinical-data-on-ava6000-at-the-european-society-for-medical 2024-09-09T14:25:23+00:00 weekly 0.7 https://trial.medpath.com/news/psyence-biomed-announces-initiation-of-first-trial-site-in-australia-for-its-phase-iib-study-of 2024-09-09T14:19:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/psyence-biomed-announces-initiation-of-first-trial-site-in-australia-for-its-phase-iib-study-of 2024-09-09T14:19:22+00:00 weekly 0.7 https://trial.medpath.com/news/innovative-medical-trial-for-treatment-of-hydrocephalus-to-lead-to-safer-outcomes-for-patients 2024-09-09T14:18:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/innovative-medical-trial-for-treatment-of-hydrocephalus-to-lead-to-safer-outcomes-for-patients 2024-09-09T14:18:44+00:00 weekly 0.7 https://trial.medpath.com/news/chinese-study-finds-radiation-alone-may-be-as-effective-as-chemoradiation-in-patients 2024-09-09T14:08:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chinese-study-finds-radiation-alone-may-be-as-effective-as-chemoradiation-in-patients 2024-09-09T14:08:35+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-s-promising-biomarker-data-and-phase-iii-trials-buy-rating-affirmed 2024-09-09T14:01:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-s-promising-biomarker-data-and-phase-iii-trials-buy-rating-affirmed 2024-09-09T14:01:03+00:00 weekly 0.7 https://trial.medpath.com/news/ruxolitinib-may-be-effective-in-refractory-chronic-gvhd-hematology-advisor 2024-09-09T13:49:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ruxolitinib-may-be-effective-in-refractory-chronic-gvhd-hematology-advisor 2024-09-09T13:49:19+00:00 weekly 0.7 https://trial.medpath.com/news/bambusa-therapeutics-inc-announces-successful-series-seed-funding-to-advance-morningstar 2024-09-09T13:34:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bambusa-therapeutics-inc-announces-successful-series-seed-funding-to-advance-morningstar 2024-09-09T13:34:09+00:00 weekly 0.7 https://trial.medpath.com/news/actuate-therapeutics-obtains-complete-responses-and-provides-update-on-clinical-trial-of 2024-09-09T13:34:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/actuate-therapeutics-obtains-complete-responses-and-provides-update-on-clinical-trial-of 2024-09-09T13:34:05+00:00 weekly 0.7 https://trial.medpath.com/news/jazz-pharmaceuticals-to-present-advancements-in-solid-tumor-oncology-research-at-esmo-2024 2024-09-09T13:33:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jazz-pharmaceuticals-to-present-advancements-in-solid-tumor-oncology-research-at-esmo-2024 2024-09-09T13:33:39+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trials-ongoing-for-asf-bird-flu-vaccines-businessworld-online 2024-09-09T13:32:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trials-ongoing-for-asf-bird-flu-vaccines-businessworld-online 2024-09-09T13:32:58+00:00 weekly 0.7 https://trial.medpath.com/news/candid-with-370m-sets-out-to-prove-bispecifics-worth-in-autoimmune-disease 2024-09-09T13:26:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/candid-with-370m-sets-out-to-prove-bispecifics-worth-in-autoimmune-disease 2024-09-09T13:26:38+00:00 weekly 0.7 https://trial.medpath.com/news/rytelotm-imetelstat-fda-approved-for-treatment-of-patients-with-low-to-intermediate-1 2024-09-09T13:25:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rytelotm-imetelstat-fda-approved-for-treatment-of-patients-with-low-to-intermediate-1 2024-09-09T13:25:16+00:00 weekly 0.7 https://trial.medpath.com/news/t2-biosystems-provides-updates-on-its-new-product-development-pipeline-progress 2024-09-09T13:25:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/t2-biosystems-provides-updates-on-its-new-product-development-pipeline-progress 2024-09-09T13:25:10+00:00 weekly 0.7 https://trial.medpath.com/news/china-s-akeso-soars-after-new-cancer-drug-beats-market-leader-in-clinical-trials 2024-09-09T13:18:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/china-s-akeso-soars-after-new-cancer-drug-beats-market-leader-in-clinical-trials 2024-09-09T13:18:26+00:00 weekly 0.7 https://trial.medpath.com/news/femasys-inc-receives-u-s-fda-clearance-to-market-femchec-r-an-innovative-diagnostic 2024-09-09T13:14:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/femasys-inc-receives-u-s-fda-clearance-to-market-femchec-r-an-innovative-diagnostic 2024-09-09T13:14:31+00:00 weekly 0.7 https://trial.medpath.com/news/epsilogen-ltd-completes-ps12-5m-series-b-expansion-european-biotechnology-magazine 2024-09-09T13:14:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/epsilogen-ltd-completes-ps12-5m-series-b-expansion-european-biotechnology-magazine 2024-09-09T13:14:30+00:00 weekly 0.7 https://trial.medpath.com/news/amgen-presents-new-data-for-first-in-class-imdelltratm-tarlatamab 2024-09-09T13:06:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/amgen-presents-new-data-for-first-in-class-imdelltratm-tarlatamab 2024-09-09T13:06:17+00:00 weekly 0.7 https://trial.medpath.com/news/evaxion-reports-69-overall-response-rate-in-its-phase-2-trial-on-lead-cancer-vaccine 2024-09-09T13:04:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/evaxion-reports-69-overall-response-rate-in-its-phase-2-trial-on-lead-cancer-vaccine 2024-09-09T13:04:00+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-showcases-advancement-of-solid-tumor-pipeline-at-esmo-2024-with-new-data-in 2024-09-09T13:02:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbvie-showcases-advancement-of-solid-tumor-pipeline-at-esmo-2024-with-new-data-in 2024-09-09T13:02:58+00:00 weekly 0.7 https://trial.medpath.com/news/chinese-monkeypox-vaccine-gets-green-light-for-clinical-trials-chinadaily-com-cn 2024-09-09T13:01:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chinese-monkeypox-vaccine-gets-green-light-for-clinical-trials-chinadaily-com-cn 2024-09-09T13:01:20+00:00 weekly 0.7 https://trial.medpath.com/news/september-2024-letter-to-shareholders-cytodyn-inc 2024-09-09T12:35:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/september-2024-letter-to-shareholders-cytodyn-inc 2024-09-09T12:35:02+00:00 weekly 0.7 https://trial.medpath.com/news/pds-biotech-to-present-updated-versatile-002-data-at-esmo-congress-2024 2024-09-09T12:34:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pds-biotech-to-present-updated-versatile-002-data-at-esmo-congress-2024 2024-09-09T12:34:03+00:00 weekly 0.7 https://trial.medpath.com/news/biostock-has-published-an-article-on-the-approved-ompd-for-cs1-in-the-eu-marketscreener 2024-09-09T12:28:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biostock-has-published-an-article-on-the-approved-ompd-for-cs1-in-the-eu-marketscreener 2024-09-09T12:28:34+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-illumina-cancer-biomarker-test-san-diego-business-journal 2024-09-09T12:28:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-illumina-cancer-biomarker-test-san-diego-business-journal 2024-09-09T12:28:18+00:00 weekly 0.7 https://trial.medpath.com/news/data-show-sustained-benefits-of-deucrictibant-for-hae-attacks-angioedema-news 2024-09-09T12:22:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/data-show-sustained-benefits-of-deucrictibant-for-hae-attacks-angioedema-news 2024-09-09T12:22:54+00:00 weekly 0.7 https://trial.medpath.com/news/amgen-will-test-obesity-drug-maritide-for-kidney-and-other-diseases-docwire-news 2024-09-09T12:21:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/amgen-will-test-obesity-drug-maritide-for-kidney-and-other-diseases-docwire-news 2024-09-09T12:21:37+00:00 weekly 0.7 https://trial.medpath.com/news/moleculin-announces-first-patients-treated-in-phase-2-clinical-trial-of-stat3-stock-titan 2024-09-09T12:20:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/moleculin-announces-first-patients-treated-in-phase-2-clinical-trial-of-stat3-stock-titan 2024-09-09T12:20:26+00:00 weekly 0.7 https://trial.medpath.com/news/agilent-unveils-biopharma-cdx-services-lab-to-accelerate-precision-medicine-stock-titan 2024-09-09T12:20:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/agilent-unveils-biopharma-cdx-services-lab-to-accelerate-precision-medicine-stock-titan 2024-09-09T12:20:24+00:00 weekly 0.7 https://trial.medpath.com/news/ub-professor-nys-researchers-developing-immunotherapy-treatment-for-alzheimer-s 2024-09-09T12:14:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ub-professor-nys-researchers-developing-immunotherapy-treatment-for-alzheimer-s 2024-09-09T12:14:32+00:00 weekly 0.7 https://trial.medpath.com/news/phase-i-study-of-safety-and-efficacy-of-allogeneic-natural-killer-cell-therapy-in-relapsed 2024-09-09T12:08:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-i-study-of-safety-and-efficacy-of-allogeneic-natural-killer-cell-therapy-in-relapsed 2024-09-09T12:08:45+00:00 weekly 0.7 https://trial.medpath.com/news/annexon-to-present-phase-2-archer-data-on-protection-of-vision-and-photoreceptors-with 2024-09-09T12:06:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/annexon-to-present-phase-2-archer-data-on-protection-of-vision-and-photoreceptors-with 2024-09-09T12:06:09+00:00 weekly 0.7 https://trial.medpath.com/news/replimune-announces-positive-pre-bla-meeting-with-fda-and-globenewswire 2024-09-09T12:04:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/replimune-announces-positive-pre-bla-meeting-with-fda-and-globenewswire 2024-09-09T12:04:09+00:00 weekly 0.7 https://trial.medpath.com/news/rezolute-s-rz358-advances-with-fda-clearance-for-study-tipranks-com 2024-09-09T11:59:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rezolute-s-rz358-advances-with-fda-clearance-for-study-tipranks-com 2024-09-09T11:59:17+00:00 weekly 0.7 https://trial.medpath.com/news/medicenna-presents-preclinical-results-from-its-il-2-super-antagonist-and-anti-pd1-il-2 2024-09-09T11:59:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medicenna-presents-preclinical-results-from-its-il-2-super-antagonist-and-anti-pd1-il-2 2024-09-09T11:59:08+00:00 weekly 0.7 https://trial.medpath.com/news/tonix-pharmaceuticals-presented-data-on-the-potential-mpox-vaccine-tnx-801-in-morningstar 2024-09-09T11:35:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tonix-pharmaceuticals-presented-data-on-the-potential-mpox-vaccine-tnx-801-in-morningstar 2024-09-09T11:35:59+00:00 weekly 0.7 https://trial.medpath.com/news/terns-pharmaceuticals-announces-positive-phase-1-clinical-trial-results-with-tern-601 2024-09-09T11:35:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/terns-pharmaceuticals-announces-positive-phase-1-clinical-trial-results-with-tern-601 2024-09-09T11:35:57+00:00 weekly 0.7 https://trial.medpath.com/news/cartesian-therapeutics-receives-fda-rare-pediatric-disease-designation-for-descartes-08 2024-09-09T11:18:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cartesian-therapeutics-receives-fda-rare-pediatric-disease-designation-for-descartes-08 2024-09-09T11:18:14+00:00 weekly 0.7 https://trial.medpath.com/news/sab-bio-provides-sab-142-clinical-trial-progress-update-at-the-european-association-for 2024-09-09T11:13:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sab-bio-provides-sab-142-clinical-trial-progress-update-at-the-european-association-for 2024-09-09T11:13:00+00:00 weekly 0.7 https://trial.medpath.com/news/akero-therapeutics-announces-first-patient-dosed-in-phase-3-synchrony-outcomes 2024-09-09T11:04:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/akero-therapeutics-announces-first-patient-dosed-in-phase-3-synchrony-outcomes 2024-09-09T11:04:11+00:00 weekly 0.7 https://trial.medpath.com/news/targeting-the-racial-disparity-in-kidney-disease 2024-09-09T11:00:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/targeting-the-racial-disparity-in-kidney-disease 2024-09-09T11:00:41+00:00 weekly 0.7 https://trial.medpath.com/news/1104-tackling-the-root-cause-of-allergic-disease-drug-target-review 2024-09-09T10:58:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/1104-tackling-the-root-cause-of-allergic-disease-drug-target-review 2024-09-09T10:58:08+00:00 weekly 0.7 https://trial.medpath.com/news/dr-sen-on-interim-ideate-lung01-data-in-extensive-stage-sclc-onclive 2024-09-09T10:47:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-sen-on-interim-ideate-lung01-data-in-extensive-stage-sclc-onclive 2024-09-09T10:47:13+00:00 weekly 0.7 https://trial.medpath.com/news/fosun-pharma-s-new-drug-wins-approval-tipranks-com 2024-09-09T10:41:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fosun-pharma-s-new-drug-wins-approval-tipranks-com 2024-09-09T10:41:09+00:00 weekly 0.7 https://trial.medpath.com/news/u-ploid-announces-breakthrough-technology-to-overcome-age-related-infertility 2024-09-09T10:23:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/u-ploid-announces-breakthrough-technology-to-overcome-age-related-infertility 2024-09-09T10:23:17+00:00 weekly 0.7 https://trial.medpath.com/news/bayer-receives-ema-approval-marketscreener 2024-09-09T10:16:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bayer-receives-ema-approval-marketscreener 2024-09-09T10:16:03+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-completes-clinical-trials-for-near-zero-emission-inhalers-businessgreen-news 2024-09-09T09:11:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-completes-clinical-trials-for-near-zero-emission-inhalers-businessgreen-news 2024-09-09T09:11:18+00:00 weekly 0.7 https://trial.medpath.com/news/immunovant-provides-update-on-graves-disease-development-program-biospace 2024-09-09T09:09:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immunovant-provides-update-on-graves-disease-development-program-biospace 2024-09-09T09:09:11+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-leklaza-combination-therapy-what-are-the-prospects-for-monotherapy-in 2024-09-09T08:50:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-leklaza-combination-therapy-what-are-the-prospects-for-monotherapy-in 2024-09-09T08:50:08+00:00 weekly 0.7 https://trial.medpath.com/news/tilt-biotherapeutics-presents-clinical-data-on-tilt-123-globenewswire 2024-09-09T07:03:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tilt-biotherapeutics-presents-clinical-data-on-tilt-123-globenewswire 2024-09-09T07:03:14+00:00 weekly 0.7 https://trial.medpath.com/news/annual-mammograms-show-superior-outcomes-in-breast-cancer-detection-and-survival-rates 2024-09-09T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/annual-mammograms-show-superior-outcomes-in-breast-cancer-detection-and-survival-rates 2024-09-09T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/diamyd-medical-to-pursue-accelerated-approval-pathway-for-type-1-diabetes-precision-medicine 2024-09-09T06:57:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/diamyd-medical-to-pursue-accelerated-approval-pathway-for-type-1-diabetes-precision-medicine 2024-09-09T06:57:57+00:00 weekly 0.7 https://trial.medpath.com/news/myongji-hospital-develops-tool-to-predict-ovarian-cancer-drug-resistance-hospital-article-kbr 2024-09-09T06:47:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/myongji-hospital-develops-tool-to-predict-ovarian-cancer-drug-resistance-hospital-article-kbr 2024-09-09T06:47:34+00:00 weekly 0.7 https://trial.medpath.com/news/cizzle-biotechnology-collaborates-with-moffitt-cancer-center-directorstalk-interviews 2024-09-09T06:38:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cizzle-biotechnology-collaborates-with-moffitt-cancer-center-directorstalk-interviews 2024-09-09T06:38:48+00:00 weekly 0.7 https://trial.medpath.com/news/chugai-seeks-additional-indication-approval-from-japan-mhlw-for-vabysmo-to-treat-angioid 2024-09-09T06:30:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chugai-seeks-additional-indication-approval-from-japan-mhlw-for-vabysmo-to-treat-angioid 2024-09-09T06:30:50+00:00 weekly 0.7 https://trial.medpath.com/news/hemogenyx-pharmaceuticals-plc-flt3-assay-ready-for-phase-i-trials-at-md-anderson 2024-09-09T06:28:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hemogenyx-pharmaceuticals-plc-flt3-assay-ready-for-phase-i-trials-at-md-anderson 2024-09-09T06:28:41+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approved-oral-jak-inhibitors-show-promise-in-treating-moderate-to-severe-atopic-dermatitis 2024-09-09T05:17:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approved-oral-jak-inhibitors-show-promise-in-treating-moderate-to-severe-atopic-dermatitis 2024-09-09T05:17:03+00:00 weekly 0.7 https://trial.medpath.com/news/global-biopharmaceutical-innovator-pharmaessentia-launches-new 2024-09-09T05:15:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/global-biopharmaceutical-innovator-pharmaessentia-launches-new 2024-09-09T05:15:38+00:00 weekly 0.7 https://trial.medpath.com/news/innate-pharma-sa-monalizumab-data-from-neocoast-2-phase-2-study-in-early-stage 2024-09-09T05:08:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/innate-pharma-sa-monalizumab-data-from-neocoast-2-phase-2-study-in-early-stage 2024-09-09T05:08:28+00:00 weekly 0.7 https://trial.medpath.com/news/poltreg-treg-cell-therapy-for-patients-with-type-1-diabetes-globenewswire 2024-09-09T05:02:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/poltreg-treg-cell-therapy-for-patients-with-type-1-diabetes-globenewswire 2024-09-09T05:02:17+00:00 weekly 0.7 https://trial.medpath.com/news/late-stage-alzheimer-s-pipeline-goes-beyond-amyloid-and-tau-biospace 2024-09-09T04:10:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/late-stage-alzheimer-s-pipeline-goes-beyond-amyloid-and-tau-biospace 2024-09-09T04:10:58+00:00 weekly 0.7 https://trial.medpath.com/news/mda-kickstart-program-launches-for-ultra-rare-neuromuscular-disease-drug-development 2024-09-09T04:01:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mda-kickstart-program-launches-for-ultra-rare-neuromuscular-disease-drug-development 2024-09-09T04:01:41+00:00 weekly 0.7 https://trial.medpath.com/news/healios-kk-advances-global-phase-3-ards-trial-tipranks-com 2024-09-09T03:58:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/healios-kk-advances-global-phase-3-ards-trial-tipranks-com 2024-09-09T03:58:53+00:00 weekly 0.7 https://trial.medpath.com/news/br-6002-by-boryung-pharmaceutical-for-cardiovascular-disease-likelihood-of-approval 2024-09-09T03:09:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/br-6002-by-boryung-pharmaceutical-for-cardiovascular-disease-likelihood-of-approval 2024-09-09T03:09:14+00:00 weekly 0.7 https://trial.medpath.com/news/senhwa-biosciences-presents-clinical-data-abstract-on-pidnarulex-at-2024-esmo-congress 2024-09-09T02:39:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/senhwa-biosciences-presents-clinical-data-abstract-on-pidnarulex-at-2024-esmo-congress 2024-09-09T02:39:41+00:00 weekly 0.7 https://trial.medpath.com/news/hutchmed-highlights-clinical-data-to-be-presented-at-esmo-congress-2024-and-the 2024-09-09T01:53:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hutchmed-highlights-clinical-data-to-be-presented-at-esmo-congress-2024-and-the 2024-09-09T01:53:41+00:00 weekly 0.7 https://trial.medpath.com/news/antennova-to-present-latest-data-of-atn-037-in-a-mini-oral-presentation-at-esmo-congress-2024 2024-09-09T00:52:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/antennova-to-present-latest-data-of-atn-037-in-a-mini-oral-presentation-at-esmo-congress-2024 2024-09-09T00:52:39+00:00 weekly 0.7 https://trial.medpath.com/news/natera-to-present-new-signateratm-colorectal-cancer-data-at-esmo-showing-10x 2024-09-09T00:34:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/natera-to-present-new-signateratm-colorectal-cancer-data-at-esmo-showing-10x 2024-09-09T00:34:38+00:00 weekly 0.7 https://trial.medpath.com/news/eisai-s-foscenvivint-shows-promise-in-pancreatic-cancer-development-pipeline 2024-09-09T00:12:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eisai-s-foscenvivint-shows-promise-in-pancreatic-cancer-development-pipeline 2024-09-09T00:12:01+00:00 weekly 0.7 https://trial.medpath.com/news/alfasigma-advances-filgotinib-maleate-development-for-igg4-related-disease-treatment 2024-09-09T00:03:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alfasigma-advances-filgotinib-maleate-development-for-igg4-related-disease-treatment 2024-09-09T00:03:06+00:00 weekly 0.7 https://trial.medpath.com/news/update-imunons-ovarian-cancer-r-d-day-to-feature-presentations-from-imnn-001-clinical-study-investigators-immunology-and-biostatistics-experts-and-executive-management 2024-09-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/update-imunons-ovarian-cancer-r-d-day-to-feature-presentations-from-imnn-001-clinical-study-investigators-immunology-and-biostatistics-experts-and-executive-management 2024-09-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/breakwater-study-shows-promise-for-encorafenib-cetuximab-plus-folfiri-in-braf-v600e-mutant-colorectal-cancer 2024-09-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakwater-study-shows-promise-for-encorafenib-cetuximab-plus-folfiri-in-braf-v600e-mutant-colorectal-cancer 2024-09-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/hr20013-demonstrates-noninferiority-in-preventing-chemo-induced-nausea-vomiting 2024-09-08T23:26:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hr20013-demonstrates-noninferiority-in-preventing-chemo-induced-nausea-vomiting 2024-09-08T23:26:15+00:00 weekly 0.7 https://trial.medpath.com/news/lecanemab-the-drug-giving-hope-to-people-at-risk-of-dementia-hmri 2024-09-08T23:25:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lecanemab-the-drug-giving-hope-to-people-at-risk-of-dementia-hmri 2024-09-08T23:25:01+00:00 weekly 0.7 https://trial.medpath.com/news/anti-pd-l1-antibody-asc22-in-combination-with-a-histone-deacetylase-inhibitor-chidamide-nature 2024-09-08T23:16:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/anti-pd-l1-antibody-asc22-in-combination-with-a-histone-deacetylase-inhibitor-chidamide-nature 2024-09-08T23:16:58+00:00 weekly 0.7 https://trial.medpath.com/news/macrogenics-announces-tamarack-phase-2-data-presentation-at-esmo-congress-2024 2024-09-08T23:15:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/macrogenics-announces-tamarack-phase-2-data-presentation-at-esmo-congress-2024 2024-09-08T23:15:07+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-combining-durvalumab-with-novel-agents-increases-pathological-responses-in 2024-09-08T23:10:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trial-combining-durvalumab-with-novel-agents-increases-pathological-responses-in 2024-09-08T23:10:30+00:00 weekly 0.7 https://trial.medpath.com/news/cantargia-new-data-from-two-clinical-studies-strongly-support-nadunolimab-efficacy-after 2024-09-08T22:21:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cantargia-new-data-from-two-clinical-studies-strongly-support-nadunolimab-efficacy-after 2024-09-08T22:21:33+00:00 weekly 0.7 https://trial.medpath.com/news/ultimovacs-announces-updated-data-analysis-on-uv1-phase-ii-globenewswire 2024-09-08T22:18:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ultimovacs-announces-updated-data-analysis-on-uv1-phase-ii-globenewswire 2024-09-08T22:18:22+00:00 weekly 0.7 https://trial.medpath.com/news/c4-therapeutics-to-present-preliminary-cft1946-monotherapy-phase-1-clinical-data-at-the 2024-09-08T22:12:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/c4-therapeutics-to-present-preliminary-cft1946-monotherapy-phase-1-clinical-data-at-the 2024-09-08T22:12:22+00:00 weekly 0.7 https://trial.medpath.com/news/summit-lung-cancer-drug-shows-striking-benefit-over-keytruda-biopharma-dive 2024-09-08T22:10:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/summit-lung-cancer-drug-shows-striking-benefit-over-keytruda-biopharma-dive 2024-09-08T22:10:49+00:00 weekly 0.7 https://trial.medpath.com/news/dr-spira-on-updated-mariposa-trial-data-in-egfr-advanced-nsclc-onclive 2024-09-08T22:07:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-spira-on-updated-mariposa-trial-data-in-egfr-advanced-nsclc-onclive 2024-09-08T22:07:11+00:00 weekly 0.7 https://trial.medpath.com/news/a-biotech-going-through-the-nose-to-treat-the-brain-plots-alternative-path-to-public-markets 2024-09-08T21:52:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-biotech-going-through-the-nose-to-treat-the-brain-plots-alternative-path-to-public-markets 2024-09-08T21:52:34+00:00 weekly 0.7 https://trial.medpath.com/news/durvalumab-combo-maintains-pfs-benefit-in-ovarian-cancer-targeted-oncology 2024-09-08T21:04:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/durvalumab-combo-maintains-pfs-benefit-in-ovarian-cancer-targeted-oncology 2024-09-08T21:04:34+00:00 weekly 0.7 https://trial.medpath.com/news/effectiveness-of-structured-multidisciplinary-long-term-care-for-pediatric-cancer-survivors 2024-09-08T20:32:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/effectiveness-of-structured-multidisciplinary-long-term-care-for-pediatric-cancer-survivors 2024-09-08T20:32:05+00:00 weekly 0.7 https://trial.medpath.com/news/a-phase-ii-trial-examining-the-safety-and-preliminary-efficacy-of-repetitive-transcranial 2024-09-08T20:30:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-phase-ii-trial-examining-the-safety-and-preliminary-efficacy-of-repetitive-transcranial 2024-09-08T20:30:06+00:00 weekly 0.7 https://trial.medpath.com/news/study-reports-2-year-survival-data-on-nivolumab-plus-relatlimab-in-nsclc 2024-09-08T19:22:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-reports-2-year-survival-data-on-nivolumab-plus-relatlimab-in-nsclc 2024-09-08T19:22:02+00:00 weekly 0.7 https://trial.medpath.com/news/fda-oked-new-drug-application-for-novel-glioblastoma-treatment-cure-today 2024-09-08T19:10:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-oked-new-drug-application-for-novel-glioblastoma-treatment-cure-today 2024-09-08T19:10:30+00:00 weekly 0.7 https://trial.medpath.com/news/research-identifies-potential-biomarkers-for-treatment-response-in-psa-hcplive 2024-09-08T18:31:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/research-identifies-potential-biomarkers-for-treatment-response-in-psa-hcplive 2024-09-08T18:31:00+00:00 weekly 0.7 https://trial.medpath.com/news/sun-pharma-s-sonidegib-shows-promise-across-multiple-cancer-indications-beyond-basal-cell-carcinoma 2024-09-08T18:28:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sun-pharma-s-sonidegib-shows-promise-across-multiple-cancer-indications-beyond-basal-cell-carcinoma 2024-09-08T18:28:51+00:00 weekly 0.7 https://trial.medpath.com/news/minovia-s-mnv-201-cell-therapy-shows-promise-for-rare-pearson-syndrome-treatment 2024-09-08T18:26:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/minovia-s-mnv-201-cell-therapy-shows-promise-for-rare-pearson-syndrome-treatment 2024-09-08T18:26:19+00:00 weekly 0.7 https://trial.medpath.com/news/first-in-class-cebranopadol-moving-to-phase-3-trials-managed-healthcare-executive 2024-09-08T18:14:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-in-class-cebranopadol-moving-to-phase-3-trials-managed-healthcare-executive 2024-09-08T18:14:14+00:00 weekly 0.7 https://trial.medpath.com/news/emicizumab-shows-promise-for-acquired-hemophilia-a-treatment-in-development-pipeline 2024-09-08T17:57:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/emicizumab-shows-promise-for-acquired-hemophilia-a-treatment-in-development-pipeline 2024-09-08T17:57:42+00:00 weekly 0.7 https://trial.medpath.com/news/rybrevant-r-amivantamab-vmjw-plus-lazcluzetm-lazertinib-show-strong-favorable 2024-09-08T17:49:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rybrevant-r-amivantamab-vmjw-plus-lazcluzetm-lazertinib-show-strong-favorable 2024-09-08T17:49:14+00:00 weekly 0.7 https://trial.medpath.com/news/risk-adjusted-net-present-value-what-is-the-current-valuation-of-deciphera 2024-09-08T17:45:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/risk-adjusted-net-present-value-what-is-the-current-valuation-of-deciphera 2024-09-08T17:45:12+00:00 weekly 0.7 https://trial.medpath.com/news/perioperative-nivolumab-may-bolster-survival-over-only-neoadjuvant-nivolumab-plus 2024-09-08T17:18:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/perioperative-nivolumab-may-bolster-survival-over-only-neoadjuvant-nivolumab-plus 2024-09-08T17:18:32+00:00 weekly 0.7 https://trial.medpath.com/news/immunotherapy-before-and-after-lung-cancer-surgery-reduces-death-risk-and-disease 2024-09-08T17:12:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immunotherapy-before-and-after-lung-cancer-surgery-reduces-death-risk-and-disease 2024-09-08T17:12:44+00:00 weekly 0.7 https://trial.medpath.com/news/il-21-promises-to-revolutionize-treatment-for-glioblastoma-pembrolizumab-trials-halted-in 2024-09-08T17:03:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/il-21-promises-to-revolutionize-treatment-for-glioblastoma-pembrolizumab-trials-halted-in 2024-09-08T17:03:02+00:00 weekly 0.7 https://trial.medpath.com/news/novel-computational-pathology-based-trop2-biomarker-for-datopotamab-deruxtecan-was 2024-09-08T16:36:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-computational-pathology-based-trop2-biomarker-for-datopotamab-deruxtecan-was 2024-09-08T16:36:17+00:00 weekly 0.7 https://trial.medpath.com/news/global-experts-share-strategies-to-enhance-lung-cancer-screening-access-and-early-detection 2024-09-08T16:30:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/global-experts-share-strategies-to-enhance-lung-cancer-screening-access-and-early-detection 2024-09-08T16:30:45+00:00 weekly 0.7 https://trial.medpath.com/news/ivonescimab-monotherapy-reduced-the-risk-of-disease-progression-or-death-by-49-morningstar 2024-09-08T16:03:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ivonescimab-monotherapy-reduced-the-risk-of-disease-progression-or-death-by-49-morningstar 2024-09-08T16:03:05+00:00 weekly 0.7 https://trial.medpath.com/news/company-announcement-markets-data 2024-09-08T15:49:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/company-announcement-markets-data 2024-09-08T15:49:26+00:00 weekly 0.7 https://trial.medpath.com/news/association-of-leucine-and-other-branched-chain-amino-acids-with-clinical-outcomes-in-nature 2024-09-08T14:58:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/association-of-leucine-and-other-branched-chain-amino-acids-with-clinical-outcomes-in-nature 2024-09-08T14:58:15+00:00 weekly 0.7 https://trial.medpath.com/news/vaxcyte-s-broad-spectrum-pneumococcal-vaccines-poised-for-market-dominance-by-2027 2024-09-08T14:34:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vaxcyte-s-broad-spectrum-pneumococcal-vaccines-poised-for-market-dominance-by-2027 2024-09-08T14:34:14+00:00 weekly 0.7 https://trial.medpath.com/news/lower-risk-mds-population-has-enduring-rbc-ti-following-imetelstat-therapy 2024-09-08T14:09:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lower-risk-mds-population-has-enduring-rbc-ti-following-imetelstat-therapy 2024-09-08T14:09:23+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-think-surgical-robotic-system-for-use-with-medacta-knee-implants-healio 2024-09-08T13:57:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-clears-think-surgical-robotic-system-for-use-with-medacta-knee-implants-healio 2024-09-08T13:57:39+00:00 weekly 0.7 https://trial.medpath.com/news/childhood-antibioticination-reduces-mortality-in-africa-contagion-live 2024-09-08T13:26:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/childhood-antibioticination-reduces-mortality-in-africa-contagion-live 2024-09-08T13:26:31+00:00 weekly 0.7 https://trial.medpath.com/news/revealed-the-bowel-cancer-breakthrough-that-could-save-young-sufferers-daily-mail 2024-09-08T13:12:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/revealed-the-bowel-cancer-breakthrough-that-could-save-young-sufferers-daily-mail 2024-09-08T13:12:44+00:00 weekly 0.7 https://trial.medpath.com/news/all-about-cholesterol-american-society-for-biochemistry-and-molecular-biology 2024-09-08T12:15:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/all-about-cholesterol-american-society-for-biochemistry-and-molecular-biology 2024-09-08T12:15:17+00:00 weekly 0.7 https://trial.medpath.com/news/alzheimer-s-drug-leqembi-promises-to-give-patients-more-time-but-they-face-a-long-road-to-treatment 2024-09-08T12:03:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alzheimer-s-drug-leqembi-promises-to-give-patients-more-time-but-they-face-a-long-road-to-treatment 2024-09-08T12:03:19+00:00 weekly 0.7 https://trial.medpath.com/news/longboard-pharmaceuticals-announces-positive-interim-analysis-results-from-the-stock-titan 2024-09-08T11:35:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/longboard-pharmaceuticals-announces-positive-interim-analysis-results-from-the-stock-titan 2024-09-08T11:35:43+00:00 weekly 0.7 https://trial.medpath.com/news/ai-platform-demonstrates-promising-results-in-treating-patient-with-rare-cancer 2024-09-08T11:31:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-platform-demonstrates-promising-results-in-treating-patient-with-rare-cancer 2024-09-08T11:31:44+00:00 weekly 0.7 https://trial.medpath.com/news/savara-announces-new-data-from-pivotal-phase-3-impala-2-trial-of-molgramostim-morningstar 2024-09-08T11:02:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/savara-announces-new-data-from-pivotal-phase-3-impala-2-trial-of-molgramostim-morningstar 2024-09-08T11:02:45+00:00 weekly 0.7 https://trial.medpath.com/news/celcuity-s-gedatolisib-projected-to-reach-155m-annual-revenue-by-2034-for-breast-cancer-treatment 2024-09-08T09:14:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/celcuity-s-gedatolisib-projected-to-reach-155m-annual-revenue-by-2034-for-breast-cancer-treatment 2024-09-08T09:14:13+00:00 weekly 0.7 https://trial.medpath.com/news/tenaya-therapeutics-gene-therapy-tn-201-shows-promise-with-projected-165m-revenue-for-cardiomyopathy-treatment 2024-09-08T09:13:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tenaya-therapeutics-gene-therapy-tn-201-shows-promise-with-projected-165m-revenue-for-cardiomyopathy-treatment 2024-09-08T09:13:04+00:00 weekly 0.7 https://trial.medpath.com/news/bristol-myers-squibb-s-myk-224-for-hypertrophic-cardiomyopathy-projects-41m-revenue-by-2035 2024-09-08T09:11:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bristol-myers-squibb-s-myk-224-for-hypertrophic-cardiomyopathy-projects-41m-revenue-by-2035 2024-09-08T09:11:56+00:00 weekly 0.7 https://trial.medpath.com/news/regulus-therapeutics-rgls-8429-projected-to-reach-213m-annual-revenue-by-2037-for-adpkd-treatment 2024-09-08T09:10:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/regulus-therapeutics-rgls-8429-projected-to-reach-213m-annual-revenue-by-2037-for-adpkd-treatment 2024-09-08T09:10:46+00:00 weekly 0.7 https://trial.medpath.com/news/jcr-pharmaceuticals-laronidase-for-hurler-syndrome-expected-to-generate-38m-by-2040 2024-09-08T09:08:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jcr-pharmaceuticals-laronidase-for-hurler-syndrome-expected-to-generate-38m-by-2040 2024-09-08T09:08:24+00:00 weekly 0.7 https://trial.medpath.com/news/iteos-therapeutics-tigit-inhibitor-belrestotug-projects-366m-peak-revenue-for-solid-tumors-by-2038 2024-09-08T09:06:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/iteos-therapeutics-tigit-inhibitor-belrestotug-projects-366m-peak-revenue-for-solid-tumors-by-2038 2024-09-08T09:06:16+00:00 weekly 0.7 https://trial.medpath.com/news/insmed-s-treprostinil-palmitil-shows-promise-for-rare-pulmonary-disorders-with-projected-66m-revenue-by-2037 2024-09-08T09:05:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/insmed-s-treprostinil-palmitil-shows-promise-for-rare-pulmonary-disorders-with-projected-66m-revenue-by-2037 2024-09-08T09:05:20+00:00 weekly 0.7 https://trial.medpath.com/news/altimmune-s-pemvidutide-projected-to-reach-759m-in-global-sales-by-2039 2024-09-08T09:03:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/altimmune-s-pemvidutide-projected-to-reach-759m-in-global-sales-by-2039 2024-09-08T09:03:31+00:00 weekly 0.7 https://trial.medpath.com/news/dupilumab-treatment-effective-for-chronic-rhinosinusitis-with-nasal-polyps-hcplive 2024-09-08T08:42:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dupilumab-treatment-effective-for-chronic-rhinosinusitis-with-nasal-polyps-hcplive 2024-09-08T08:42:07+00:00 weekly 0.7 https://trial.medpath.com/news/beigene-s-bgb-16673-shows-promise-in-blood-cancer-treatment-with-projected-9m-revenue-by-2037 2024-09-08T08:39:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/beigene-s-bgb-16673-shows-promise-in-blood-cancer-treatment-with-projected-9m-revenue-by-2037 2024-09-08T08:39:51+00:00 weekly 0.7 https://trial.medpath.com/news/amgen-s-maridebart-cafraglutide-projected-to-reach-527-million-in-us-sales-by-2039 2024-09-08T08:33:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/amgen-s-maridebart-cafraglutide-projected-to-reach-527-million-in-us-sales-by-2039 2024-09-08T08:33:30+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-s-atrasentan-shows-promise-with-projected-229m-revenue-by-2033-for-kidney-diseases 2024-09-08T08:32:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-s-atrasentan-shows-promise-with-projected-229m-revenue-by-2033-for-kidney-diseases 2024-09-08T08:32:18+00:00 weekly 0.7 https://trial.medpath.com/news/ideaya-s-ide-397-shows-promise-in-multiple-solid-tumors-with-47m-revenue-projection-by-2037 2024-09-08T08:29:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ideaya-s-ide-397-shows-promise-in-multiple-solid-tumors-with-47m-revenue-projection-by-2037 2024-09-08T08:29:17+00:00 weekly 0.7 https://trial.medpath.com/news/study-shows-how-nanorobots-could-prevent-strokes-newsbytes 2024-09-08T08:24:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-shows-how-nanorobots-could-prevent-strokes-newsbytes 2024-09-08T08:24:53+00:00 weekly 0.7 https://trial.medpath.com/news/fda-rejection-of-mdma-could-fuel-black-market-demand-warns-ceo-of-women-s 2024-09-08T08:08:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-rejection-of-mdma-could-fuel-black-market-demand-warns-ceo-of-women-s 2024-09-08T08:08:56+00:00 weekly 0.7 https://trial.medpath.com/news/mesa-lab-testing-new-leg-wound-care-products-eastvalleytribune-com 2024-09-08T07:07:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mesa-lab-testing-new-leg-wound-care-products-eastvalleytribune-com 2024-09-08T07:07:26+00:00 weekly 0.7 https://trial.medpath.com/news/non-invasive-optoacoustic-imaging-of-glycogen-storage-and-muscle-degeneration-in-late 2024-09-08T06:45:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/non-invasive-optoacoustic-imaging-of-glycogen-storage-and-muscle-degeneration-in-late 2024-09-08T06:45:42+00:00 weekly 0.7 https://trial.medpath.com/news/spain-pharma-company-key-in-life-saving-drug-euro-weekly-news 2024-09-08T05:31:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/spain-pharma-company-key-in-life-saving-drug-euro-weekly-news 2024-09-08T05:31:54+00:00 weekly 0.7 https://trial.medpath.com/news/first-comprehensive-review-of-sma-drugs-offers-long-term-insights-outcome-gaps 2024-09-08T02:49:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-comprehensive-review-of-sma-drugs-offers-long-term-insights-outcome-gaps 2024-09-08T02:49:33+00:00 weekly 0.7 https://trial.medpath.com/news/dose-justification-for-asciminib-in-patients-with-philadelphia-chromosome-positive-chronic 2024-09-08T01:39:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dose-justification-for-asciminib-in-patients-with-philadelphia-chromosome-positive-chronic 2024-09-08T01:39:53+00:00 weekly 0.7 https://trial.medpath.com/news/levicept-levi-04-reduces-osteoarthritis-pain-2-minute-medicine 2024-09-07T23:48:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/levicept-levi-04-reduces-osteoarthritis-pain-2-minute-medicine 2024-09-07T23:48:11+00:00 weekly 0.7 https://trial.medpath.com/news/antibody-drug-conjugate-i-dxd-shows-meaningful-response-in-patients-with-extensive-stage 2024-09-07T22:18:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/antibody-drug-conjugate-i-dxd-shows-meaningful-response-in-patients-with-extensive-stage 2024-09-07T22:18:04+00:00 weekly 0.7 https://trial.medpath.com/news/semaglutide-hydrogel-may-cut-diabetes-shots-to-monthly-mirage-news 2024-09-07T22:03:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/semaglutide-hydrogel-may-cut-diabetes-shots-to-monthly-mirage-news 2024-09-07T22:03:23+00:00 weekly 0.7 https://trial.medpath.com/news/merck-daiichi-post-trial-data-for-lung-cancer-drug-nyse-mrk-seeking-alpha 2024-09-07T21:13:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-daiichi-post-trial-data-for-lung-cancer-drug-nyse-mrk-seeking-alpha 2024-09-07T21:13:37+00:00 weekly 0.7 https://trial.medpath.com/news/this-week-in-ophthalmology-week-of-september-1-2024 2024-09-07T21:06:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/this-week-in-ophthalmology-week-of-september-1-2024 2024-09-07T21:06:17+00:00 weekly 0.7 https://trial.medpath.com/news/high-risk-cll-subgroups-see-benefits-with-liso-cel-targeted-oncology 2024-09-07T21:05:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/high-risk-cll-subgroups-see-benefits-with-liso-cel-targeted-oncology 2024-09-07T21:05:27+00:00 weekly 0.7 https://trial.medpath.com/news/tryptamine-therapeutics-sets-date-for-agm-advances-clinical-trials-tipranks-com 2024-09-07T19:24:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tryptamine-therapeutics-sets-date-for-agm-advances-clinical-trials-tipranks-com 2024-09-07T19:24:16+00:00 weekly 0.7 https://trial.medpath.com/news/recreational-drug-use-tied-to-repeat-cardiovascular-events-medical-xpress 2024-09-07T19:21:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/recreational-drug-use-tied-to-repeat-cardiovascular-events-medical-xpress 2024-09-07T19:21:14+00:00 weekly 0.7 https://trial.medpath.com/news/effect-of-adding-electroacupuncture-to-standard-triple-antiemetic-therapy-on-pubmed 2024-09-07T18:49:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/effect-of-adding-electroacupuncture-to-standard-triple-antiemetic-therapy-on-pubmed 2024-09-07T18:49:55+00:00 weekly 0.7 https://trial.medpath.com/news/brentuximab-vedotin-triplet-continues-to-improve-r-r-diffuse-large-b-cell-lymphoma-outcomes 2024-09-07T18:39:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/brentuximab-vedotin-triplet-continues-to-improve-r-r-diffuse-large-b-cell-lymphoma-outcomes 2024-09-07T18:39:20+00:00 weekly 0.7 https://trial.medpath.com/news/multicenter-radio-multiomic-analysis-for-predicting-breast-cancer-outcome-and-unravelling 2024-09-07T18:36:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/multicenter-radio-multiomic-analysis-for-predicting-breast-cancer-outcome-and-unravelling 2024-09-07T18:36:43+00:00 weekly 0.7 https://trial.medpath.com/news/buy-rating-maintained-for-unicycive-therapeutics-amidst-olc-nda-submission-and-strong 2024-09-07T18:07:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/buy-rating-maintained-for-unicycive-therapeutics-amidst-olc-nda-submission-and-strong 2024-09-07T18:07:51+00:00 weekly 0.7 https://trial.medpath.com/news/immunic-drug-targeting-post-covid-syndrome-in-phase-2-trial-icymi-nasdaq-imux 2024-09-07T17:16:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immunic-drug-targeting-post-covid-syndrome-in-phase-2-trial-icymi-nasdaq-imux 2024-09-07T17:16:26+00:00 weekly 0.7 https://trial.medpath.com/news/global-survey-reveals-persistent-barriers-to-lung-cancer-biomarker-testing-despite-growing-recognition 2024-09-07T17:07:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/global-survey-reveals-persistent-barriers-to-lung-cancer-biomarker-testing-despite-growing-recognition 2024-09-07T17:07:12+00:00 weekly 0.7 https://trial.medpath.com/news/frontline-golcadomide-r-chop-combo-elicits-antitumor-activity-in-aggressive-b-cell-lymphoma 2024-09-07T17:06:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/frontline-golcadomide-r-chop-combo-elicits-antitumor-activity-in-aggressive-b-cell-lymphoma 2024-09-07T17:06:41+00:00 weekly 0.7 https://trial.medpath.com/news/health-ministry-approves-introduction-of-new-shorter-more-efficacious-treatment-regimen-for 2024-09-07T16:38:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/health-ministry-approves-introduction-of-new-shorter-more-efficacious-treatment-regimen-for 2024-09-07T16:38:36+00:00 weekly 0.7 https://trial.medpath.com/news/intelligent-bio-solutions-advances-in-fda-approval-process-tipranks-com 2024-09-07T16:35:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intelligent-bio-solutions-advances-in-fda-approval-process-tipranks-com 2024-09-07T16:35:22+00:00 weekly 0.7 https://trial.medpath.com/news/baseline-characteristics-and-maintenance-therapy-choice-on-symptom-control-reliever 2024-09-07T16:27:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/baseline-characteristics-and-maintenance-therapy-choice-on-symptom-control-reliever 2024-09-07T16:27:49+00:00 weekly 0.7 https://trial.medpath.com/news/fda-official-clarifies-cgmp-expectations-for-investigational-drugs-raps 2024-09-07T16:00:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-official-clarifies-cgmp-expectations-for-investigational-drugs-raps 2024-09-07T16:00:21+00:00 weekly 0.7 https://trial.medpath.com/news/alzheimer-s-new-csu-treatment-could-be-game-changing-tool-the-denver-post 2024-09-07T15:48:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alzheimer-s-new-csu-treatment-could-be-game-changing-tool-the-denver-post 2024-09-07T15:48:23+00:00 weekly 0.7 https://trial.medpath.com/news/ifinatamab-deruxtecan-continues-to-demonstrate-promising-objective-response-rates-in 2024-09-07T15:35:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ifinatamab-deruxtecan-continues-to-demonstrate-promising-objective-response-rates-in 2024-09-07T15:35:45+00:00 weekly 0.7 https://trial.medpath.com/news/cbd-could-effectively-treat-leigh-syndrome-prolong-life-legal-reader 2024-09-07T15:13:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cbd-could-effectively-treat-leigh-syndrome-prolong-life-legal-reader 2024-09-07T15:13:57+00:00 weekly 0.7 https://trial.medpath.com/news/the-oncfive-top-oncology-articles-for-the-week-of-9-1-onclive 2024-09-07T13:58:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-oncfive-top-oncology-articles-for-the-week-of-9-1-onclive 2024-09-07T13:58:51+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-experience-with-duchenne-muscular-dystrophy-gene-therapy-cgtlive-r 2024-09-07T13:09:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/real-world-experience-with-duchenne-muscular-dystrophy-gene-therapy-cgtlive-r 2024-09-07T13:09:25+00:00 weekly 0.7 https://trial.medpath.com/news/us-ipo-week-ahead-a-pair-of-biotechs-plan-to-complete-200-million-deals 2024-09-07T11:49:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/us-ipo-week-ahead-a-pair-of-biotechs-plan-to-complete-200-million-deals 2024-09-07T11:49:18+00:00 weekly 0.7 https://trial.medpath.com/news/ers-congress-2024-addresses-critical-ethical-challenges-of-ai-in-clinical-decision-making 2024-09-07T11:44:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ers-congress-2024-addresses-critical-ethical-challenges-of-ai-in-clinical-decision-making 2024-09-07T11:44:35+00:00 weekly 0.7 https://trial.medpath.com/news/bowel-cancer-trial-sees-all-patients-disease-free-in-huge-breakthrough-ladbible 2024-09-07T11:15:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bowel-cancer-trial-sees-all-patients-disease-free-in-huge-breakthrough-ladbible 2024-09-07T11:15:36+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-to-sanbexin-for-acute-ischemic-stroke 2024-09-07T10:58:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-breakthrough-therapy-designation-to-sanbexin-for-acute-ischemic-stroke 2024-09-07T10:58:46+00:00 weekly 0.7 https://trial.medpath.com/news/the-evolution-and-clinical-applications-of-mrd-testing-in-lymphoma-pharmacy-times 2024-09-07T10:58:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-evolution-and-clinical-applications-of-mrd-testing-in-lymphoma-pharmacy-times 2024-09-07T10:58:46+00:00 weekly 0.7 https://trial.medpath.com/news/what-happened-in-optometry-this-week-september-2-september-6 2024-09-07T10:49:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/what-happened-in-optometry-this-week-september-2-september-6 2024-09-07T10:49:20+00:00 weekly 0.7 https://trial.medpath.com/news/how-rheumatoid-arthritis-and-down-syndrome-are-helping-researchers-find-treatments-for-alzheimer-s 2024-09-07T10:48:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/how-rheumatoid-arthritis-and-down-syndrome-are-helping-researchers-find-treatments-for-alzheimer-s 2024-09-07T10:48:08+00:00 weekly 0.7 https://trial.medpath.com/news/spidol-study-protocol-for-the-assessment-of-intrathecal-ziconotide-antalgic-efficacy-for-trials 2024-09-07T10:35:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/spidol-study-protocol-for-the-assessment-of-intrathecal-ziconotide-antalgic-efficacy-for-trials 2024-09-07T10:35:20+00:00 weekly 0.7 https://trial.medpath.com/news/csf-proteomics-hints-at-how-apoe4-promotes-ad-and-how-a-drug-hinders-it-alzforum 2024-09-07T10:29:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/csf-proteomics-hints-at-how-apoe4-promotes-ad-and-how-a-drug-hinders-it-alzforum 2024-09-07T10:29:59+00:00 weekly 0.7 https://trial.medpath.com/news/ai-deep-learning-models-show-promise-in-accelerating-lung-cancer-biomarker-detection 2024-09-07T10:01:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-deep-learning-models-show-promise-in-accelerating-lung-cancer-biomarker-detection 2024-09-07T10:01:19+00:00 weekly 0.7 https://trial.medpath.com/news/an-excellent-outcome-tavr-safe-and-effective-for-patients-in-their-nineties 2024-09-07T09:42:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/an-excellent-outcome-tavr-safe-and-effective-for-patients-in-their-nineties 2024-09-07T09:42:16+00:00 weekly 0.7 https://trial.medpath.com/news/novel-gene-therapies-and-transplant-options-reshape-sickle-cell-disease-treatment-landscape 2024-09-07T09:42:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-gene-therapies-and-transplant-options-reshape-sickle-cell-disease-treatment-landscape 2024-09-07T09:42:00+00:00 weekly 0.7 https://trial.medpath.com/news/2024-nccn-prostate-cancer-guidelines-updates-in-m1-cspc-treatment-urotoday 2024-09-07T09:32:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/2024-nccn-prostate-cancer-guidelines-updates-in-m1-cspc-treatment-urotoday 2024-09-07T09:32:43+00:00 weekly 0.7 https://trial.medpath.com/news/billionaires-are-buying-viking-therapeutics-stock-left-and-right-should-you-follow-their-lead 2024-09-07T09:29:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/billionaires-are-buying-viking-therapeutics-stock-left-and-right-should-you-follow-their-lead 2024-09-07T09:29:33+00:00 weekly 0.7 https://trial.medpath.com/news/study-compares-safety-of-jak-inhibitors-between-adolescent-adult-patients-hcplive 2024-09-07T09:23:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-compares-safety-of-jak-inhibitors-between-adolescent-adult-patients-hcplive 2024-09-07T09:23:34+00:00 weekly 0.7 https://trial.medpath.com/news/weekly-review-neffy-pre-ordering-launches-trofinetide-data-and-more 2024-09-07T08:44:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/weekly-review-neffy-pre-ordering-launches-trofinetide-data-and-more 2024-09-07T08:44:05+00:00 weekly 0.7 https://trial.medpath.com/news/research-suggests-psychedelics-are-well-tolerated-but-calls-for-improved-monitoring 2024-09-07T08:28:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/research-suggests-psychedelics-are-well-tolerated-but-calls-for-improved-monitoring 2024-09-07T08:28:01+00:00 weekly 0.7 https://trial.medpath.com/news/bioxcel-therapeutics-earns-buy-rating-on-promising-clinical-trials-and-market-potential 2024-09-07T08:27:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bioxcel-therapeutics-earns-buy-rating-on-promising-clinical-trials-and-market-potential 2024-09-07T08:27:14+00:00 weekly 0.7 https://trial.medpath.com/news/sec-form-424b4-filed-by-qualigen-therapeutics-inc-quantisnow 2024-09-07T08:03:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sec-form-424b4-filed-by-qualigen-therapeutics-inc-quantisnow 2024-09-07T08:03:34+00:00 weekly 0.7 https://trial.medpath.com/news/reagan-udall-foundation-for-fda-facilitates-discussion-on-urgent-needs-in-ptsd-therapy 2024-09-07T08:01:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/reagan-udall-foundation-for-fda-facilitates-discussion-on-urgent-needs-in-ptsd-therapy 2024-09-07T08:01:48+00:00 weekly 0.7 https://trial.medpath.com/news/managing-toxicities-in-cll-treatment-expert-insights-on-bcl2-and-btk-inhibitor-selection 2024-09-07T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/managing-toxicities-in-cll-treatment-expert-insights-on-bcl2-and-btk-inhibitor-selection 2024-09-07T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/depression-anxiety-improve-in-patients-enrolled-in-care-personalized-to-their-symptoms 2024-09-07T07:56:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/depression-anxiety-improve-in-patients-enrolled-in-care-personalized-to-their-symptoms 2024-09-07T07:56:17+00:00 weekly 0.7 https://trial.medpath.com/news/neurologylive-r-friday-5-september-6-2024 2024-09-07T07:10:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neurologylive-r-friday-5-september-6-2024 2024-09-07T07:10:45+00:00 weekly 0.7 https://trial.medpath.com/news/cgtlive-r-s-weekly-rewind-september-6-2024 2024-09-07T07:06:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cgtlive-r-s-weekly-rewind-september-6-2024 2024-09-07T07:06:38+00:00 weekly 0.7 https://trial.medpath.com/news/mrna-car-t-descartes-08-s-potential-for-treating-myasthenia-gravis-cgtlive-r 2024-09-07T06:33:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mrna-car-t-descartes-08-s-potential-for-treating-myasthenia-gravis-cgtlive-r 2024-09-07T06:33:51+00:00 weekly 0.7 https://trial.medpath.com/news/longer-duration-of-adjuvant-trastuzumab-may-further-improve-dfs-rates-in-erbb2 2024-09-07T06:03:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/longer-duration-of-adjuvant-trastuzumab-may-further-improve-dfs-rates-in-erbb2 2024-09-07T06:03:11+00:00 weekly 0.7 https://trial.medpath.com/news/gene-silencer-drug-shows-promise-in-treating-heart-condition-laboratory-equipment 2024-09-07T05:37:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gene-silencer-drug-shows-promise-in-treating-heart-condition-laboratory-equipment 2024-09-07T05:37:50+00:00 weekly 0.7 https://trial.medpath.com/news/d-vrd-improves-mrd-negativity-rates-in-newly-diagnosed-transplant-eligible-myeloma 2024-09-07T05:14:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/d-vrd-improves-mrd-negativity-rates-in-newly-diagnosed-transplant-eligible-myeloma 2024-09-07T05:14:09+00:00 weekly 0.7 https://trial.medpath.com/news/dr-ornstein-on-the-use-of-io-tki-doublets-in-non-ccrcc-onclive 2024-09-07T05:14:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-ornstein-on-the-use-of-io-tki-doublets-in-non-ccrcc-onclive 2024-09-07T05:14:07+00:00 weekly 0.7 https://trial.medpath.com/news/access-to-care-issues-complicate-prescribing-obesity-medications-clinical-advisor 2024-09-07T04:34:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/access-to-care-issues-complicate-prescribing-obesity-medications-clinical-advisor 2024-09-07T04:34:46+00:00 weekly 0.7 https://trial.medpath.com/news/vor-biopharma-s-promising-clinical-trials-and-strategic-developments-merit-a-buy-rating 2024-09-07T04:24:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vor-biopharma-s-promising-clinical-trials-and-strategic-developments-merit-a-buy-rating 2024-09-07T04:24:57+00:00 weekly 0.7 https://trial.medpath.com/news/nccn-adds-denileukin-diftitox-to-ctcl-clinical-practice-guidelines-in-oncology-onclive 2024-09-07T04:08:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nccn-adds-denileukin-diftitox-to-ctcl-clinical-practice-guidelines-in-oncology-onclive 2024-09-07T04:08:30+00:00 weekly 0.7 https://trial.medpath.com/news/new-fda-approved-device-offers-hope-for-chronic-pain-sufferers 2024-09-07T04:00:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-fda-approved-device-offers-hope-for-chronic-pain-sufferers 2024-09-07T04:00:04+00:00 weekly 0.7 https://trial.medpath.com/news/text-messaging-shows-promise-for-lung-cancer-screening-eligibility-assessment-but-equity-gaps-persist 2024-09-07T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/text-messaging-shows-promise-for-lung-cancer-screening-eligibility-assessment-but-equity-gaps-persist 2024-09-07T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/study-reveals-higher-healthcare-barriers-for-chronic-liver-disease-patients-compared-to-other-chronic-conditions 2024-09-07T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-reveals-higher-healthcare-barriers-for-chronic-liver-disease-patients-compared-to-other-chronic-conditions 2024-09-07T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/obesity-drug-startup-raises-67m-vor-s-shielded-transplant-shows-promise 2024-09-07T03:54:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/obesity-drug-startup-raises-67m-vor-s-shielded-transplant-shows-promise 2024-09-07T03:54:39+00:00 weekly 0.7 https://trial.medpath.com/news/long-term-safety-and-efficacy-evaluation-of-travoprost-intracameral-implant-based-on 2024-09-07T03:10:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/long-term-safety-and-efficacy-evaluation-of-travoprost-intracameral-implant-based-on 2024-09-07T03:10:30+00:00 weekly 0.7 https://trial.medpath.com/news/advisory-committee-meeting-for-oral-sulopenem-occurring-september-9-2024 2024-09-07T03:04:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/advisory-committee-meeting-for-oral-sulopenem-occurring-september-9-2024 2024-09-07T03:04:22+00:00 weekly 0.7 https://trial.medpath.com/news/data-support-increased-subcutaneous-rituximab-use-in-non-hodgkin-lymphoma 2024-09-07T03:00:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/data-support-increased-subcutaneous-rituximab-use-in-non-hodgkin-lymphoma 2024-09-07T03:00:54+00:00 weekly 0.7 https://trial.medpath.com/news/advanced-treatment-strategies-show-promise-in-improving-ptcl-patient-outcomes 2024-09-07T03:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/advanced-treatment-strategies-show-promise-in-improving-ptcl-patient-outcomes 2024-09-07T03:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/donor-human-milk-for-preventing-necrotising-enterocolitis-in-very-preterm-or-very-low-pubmed 2024-09-07T02:43:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/donor-human-milk-for-preventing-necrotising-enterocolitis-in-very-preterm-or-very-low-pubmed 2024-09-07T02:43:46+00:00 weekly 0.7 https://trial.medpath.com/news/managing-drug-drug-interactions-so-many-drugs-so-little-evidence-jama-network 2024-09-07T01:43:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/managing-drug-drug-interactions-so-many-drugs-so-little-evidence-jama-network 2024-09-07T01:43:53+00:00 weekly 0.7